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Laboratory Testing for the Diagnosis of HIV Infection: 
Updated Recommendations 
A. Executive Summary 
This document updates recommendations for HIV testing by laboratories in the United States 
and offers approaches for reporting test results to persons ordering HIV tests and to public health 
authorities. The recommended algorithm is a sequence of tests used in combination to improve 
the accuracy of the laboratory diagnosis of HIV based on testing of serum or plasma specimens. 
The Centers for Disease Control and Prevention (CDC) previously published guidelines for the 
serodiagnosis of HIV Type 1 infections in 1989, guidelines for testing for antibodies for HIV 
Type 2 in 1992, and protocols for confirmation of reactive rapid antibody test results in 2004.1-3 
These previous guidelines employed only tests for HIV antibodies.1-3 The updated 
recommendations also include tests for HIV antigens and HIV nucleic acid because studies from 
populations at high risk for HIV demonstrate that antibody testing alone might miss a 
considerable percentage of HIV infections detectable by virologic tests.4-10  
CDC and the Association of Public Health Laboratories (APHL) have issued these 
recommendations based on HIV tests approved by the Food and Drug Administration (FDA) as 
of December 2012 and scientific evidence, laboratory experience, and expert opinion collected 
from 2007 through December 2013. These recommendations do not include the rapid HIV-
1/HIV-2 antigen/antibody combination test approved by the FDA in August 2013 (for which 
evidence of performance in the algorithm was insufficient) or HIV-2 nucleic acid tests (NATs), 
which lack FDA approval.  
These updated recommendations for HIV testing are necessary because of 
• FDA approval of improved HIV assays that allow detection of HIV sooner after infection 
than previous immunoassays;11-14 
• evidence that relying on Western blot or indirect immunofluorescence assay (IFA) for 
confirmation of reactive initial immunoassay results can produce false-negative or 
indeterminate results early in the course of HIV infection;4-6,15-18 
• recognition that risk of HIV transmission from persons with acute and early infection is 
much higher than that from persons with established infection;19-22 
• recent indications for the clinical benefits from antiretroviral treatment (ART) of all 
persons with HIV infection, including those with acute infection;23-26 and  
• demonstration that the majority of HIV-2 infections detected by available HIV antibody 
immunoassays are misclassified as HIV-1 by the HIV-1 Western blot.27-29 
This report provides recommendations to laboratory personnel on the use of FDA-approved 
assays for the diagnosis of HIV infection in adults and children >24 months of age (Box 1). In 
brief, testing begins with a combination immunoassay that detects HIV-1 and HIV-2 antibodies 
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and HIV-1 p24 antigen. All specimens reactive on this initial assay undergo supplemental testing 
with an immunoassay that differentiates HIV-1 from HIV-2 antibodies. Specimens that are 
reactive on the initial immunoassay and nonreactive or indeterminate on the antibody 
differentiation assay proceed to HIV-1 nucleic acid testing for resolution. The results of this 
algorithm may be used to identify persons likely to benefit from treatment, to reassure persons 
who are uninfected, and for reporting evidence of HIV infection to public health authorities. 
The recommended algorithm has several advantages over previous recommendations, including 
• more accurate laboratory diagnosis of acute HIV-1 infection, 
• equally accurate laboratory diagnosis of established HIV-1 infection, 
• more accurate laboratory diagnosis of HIV-2 infection, 
• fewer indeterminate results, and 
• faster turnaround time for most test results. 
The HIV-1 Western blot and HIV-1 IFA, previously recommended to make a laboratory 
diagnosis of HIV-1 infection, are no longer part of the recommended algorithm. Positive results 
from the recommended algorithm indicate the need for HIV medical care and an initial 
evaluation that includes additional laboratory tests (such as HIV-1 viral load, CD4+ T-
lymphocyte determination, and an antiretroviral resistance assay) to confirm the presence of 
HIV-1 infection, to stage HIV disease, and to assist in the selection of an initial antiretroviral 
drug regimen.23 Because no diagnostic test or algorithm can be completely accurate in all cases 
of HIV infection, inconsistent or conflicting test results obtained during the clinical evaluation 
may warrant additional testing of follow-up specimens.  
Anticipating continued improvements in laboratory diagnostic techniques, CDC and APHL will 
monitor the introduction and FDA approval of diagnostic assays for HIV infection and update 
these recommendations when necessary. CDC and APHL will continue to monitor the 
performance of the laboratory testing algorithm and review the performance of the recommended 
algorithm at least every five years.  
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Box 1. Recommended Laboratory HIV Testing Algorithm for Serum or Plasma Specimens 
 
1. Laboratories should conduct initial testing for HIV with an FDA-approved antigen/antibody 
combination immunoassaya that detects HIV-1 and HIV-2 antibodies and HIV-1 p24 antigen to screen 
for established infection with HIV-1 or HIV-2 and for acute HIV-1 infection. No further testing is 
required for specimens that are nonreactive on the initial immunoassay. 
2. Specimens with a reactive antigen/antibody combination immunoassay result (or repeatedly reactive, if 
repeat testing is recommended by the manufacturer or required by regulatory authorities) should be 
tested with an FDA-approved antibody immunoassay that differentiates HIV-1 antibodies from HIV-2 
antibodies. Reactive results on the initial antigen/antibody combination immunoassay and the HIV-
1/HIV-2 antibody differentiation immunoassay should be interpreted as positive for HIV-1 antibodies, 
HIV-2 antibodies, or HIV antibodies, undifferentiated. 
3. Specimens that are reactive on the initial antigen/antibody combination immunoassay and nonreactive 
or indeterminate on the HIV-1/HIV-2 antibody differentiation immunoassay should be tested with an 
FDA-approved HIV-1 nucleic acid test (NAT). 
• A reactive HIV-1 NAT result and nonreactive HIV-1/HIV-2 antibody differentiation 
immunoassay result indicates laboratory evidence for acute HIV-1 infection. 
• A reactive HIV-1 NAT result and indeterminate HIV-1/HIV-2 antibody differentiation 
immunoassay result indicates the presence of HIV-1 infection confirmed by HIV-1 NAT. 
• A negative HIV-1 NAT result and nonreactive or indeterminate HIV-1/HIV-2 antibody 
differentiation immunoassay result indicates a false-positive result on the initial immunoassay.b  
4. Laboratories should use this same testing algorithm, beginning with an antigen/antibody combination 
immunoassay, with serum or plasma specimens submitted for testing after a reactive (preliminary 
positive) result from any rapid HIV test.  
a Exception: As of April 2014, data are insufficient to recommend use of the FDA-approved single-use rapid HIV-
1/HIV-2 antigen/antibody combination immunoassay as the initial assay in the algorithm. 
b See Section M, Additional Considerations, for a discussion of issues related to acute HIV-2 infection. 
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B. Introduction 
As of 2010, an estimated 1.1 million persons in the United States were living with human 
immunodeficiency virus (HIV) infection, of whom an estimated 181,000 were unaware of their 
infection.30 Approximately 49,000 new HIV diagnoses are reported to CDC each year, and the 
estimated number of new infections has remained stable at approximately 50,000 annually from 
2008 to 2010.31,32 As of 2009, an estimated 83 million adults aged 18 to 64 years reported they 
had been tested for HIV.33 Accurate laboratory diagnosis of HIV is essential to identify persons 
who could benefit from treatment, to reassure persons who are uninfected, and to reduce HIV 
transmission.34 
C. Audience 
These recommendations describe the types and sequence of laboratory assays used to make the 
laboratory diagnosis of acute HIV-1 infection, established HIV-1 infection, and HIV-2 infection. 
They are intended for use by laboratories authorized to conduct testing on serum or plasma 
specimens with assays categorized as moderate or high complexity under the Clinical Laboratory 
Improvement Amendments of 1988 (CLIA).35  
D. Scope 
These updated recommendations are intended only for testing of serum or plasma specimens 
from adults and children aged 2 years or older. Because maternal antibodies against HIV might 
be present in uninfected infants born to HIV-infected mothers,36,37 specific recommendations to 
establish the presence or absence of the diagnosis of HIV infection in infants are described 
elsewhere.38 These updated recommendations do not address methods or strategies for screening 
blood or organ donors for HIV infection; the Food and Drug Administration (FDA) and U.S. 
Public Health Service (USPHS) have issued separate guidance and recommendations on this 
topic.39-41  
E. Background and Rationale 
Accurate laboratory diagnosis of HIV infection relies on testing algorithms that maximize overall 
sensitivity and specificity by employing a sequence of tests in combination and applying 
decision rules for resolving discordant test results.42 Since 1989, the diagnostic algorithm for 
HIV testing in the United States recommended by CDC and the Association of Public Health 
Laboratories (APHL) initiated testing with a sensitive HIV-1 antibody immunoassay. Specimens 
with repeatedly reactive initial immunoassays were then tested with a more specific HIV-1 
antibody test, either the HIV-1 Western blot or HIV-1 indirect immunofluorescence assay (IFA), 
to validate those results.1 In 1992, CDC recommended specific testing for both HIV-1 and HIV-2 
antibodies if demographic or behavioral information suggested that HIV-2 infection might be 
present, if there was clinical evidence or suspicion of HIV disease in the absence of a positive 
test for antibodies to HIV-1, and in cases in which the HIV-1 Western blot exhibited an unusual 
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indeterminate pattern.2 At that time, CDC also recommended that laboratories initiating testing 
with an HIV-1/HIV-2 antibody immunoassay conduct additional, more specific tests to detect the 
presence of antibodies against HIV-2 if the HIV-1 Western blot was negative or indeterminate.2 
In 2004, CDC recommended confirmation of all reactive rapid HIV test results with either HIV-1 
Western blot or HIV-1 IFA, irrespective of results of intermediate immunoassays that may have 
been conducted.3  
Since those recommendations were issued, improved immunoassays (Box 2), an HIV-1 NAT, 
and a differentiation immunoassay that distinguishes HIV-1 from HIV-2 antibodies received 
FDA approval for use in the diagnosis of HIV infections.43,44 These developments prompted re-
evaluation of recommendations for HIV diagnostic testing. 
Box 2. Evolution of HIV Immunoassay Technology 
HIV immunoassays based on different design principles are generally grouped into “generations”: 
• 1st generation—All antigens used to bind HIV antibodies are from a lysate of HIV-1 viruses grown 
in cell culture. An indirect immunoassay format employs labeled antihuman IgG for detection of 
IgG antibodies. Significant specimen dilution is required to overcome cross-reactivity with cellular 
protein contaminants. Examples commercially available in the United States as of May 2014 
include the HIV-1 Western blot and the HIV-1 IFA.  
• 2nd generation—Synthetic peptide or recombinant protein antigens alone or combined with viral 
lysates are used to bind HIV antibodies. An indirect immunoassay format employs labeled 
antihuman IgG or protein A (which binds to IgG with high affinity45) for detection of IgG 
antibodies. Design of the specific antigenic epitopes improves sensitivity for HIV-1 group O and 
HIV-2; eliminating cellular antigens that contaminate viral lysates improves specificity by 
eliminating cross-reactivity with cellular proteins. Examples commercially available in the United 
States as of May 2014 include one HIV-1 enzyme immunoassay and six rapid HIV antibody tests. 
• 3rd generation—Synthetic peptide or recombinant protein antigens are used to bind HIV antibodies 
in an immunometric antigen sandwich format (HIV antibodies in the specimen bind to HIV 
antigens on the assay substrate and to antigens conjugated to indicator molecules). This allows 
detection of IgM and IgG antibodies. Lower sample dilutions and the ability to detect IgM 
antibodies (which are expressed before IgG antibodies) increase sensitivity during early 
seroconversion. Examples commercially available in the United States as of May 2014 include one 
HIV-1/HIV-2 enzyme immunoassay and two HIV-1/HIV-2 chemiluminescent immunoassays. 
• 4th generation—Synthetic peptide or recombinant protein antigens are used in the same antigen 
sandwich format as 3rd generation assays to detect IgM and IgG antibodies, and monoclonal 
antibodies are also included to detect p24 antigen. Inclusion of p24 antigen capture allows detection 
of HIV-1 infection before seroconversion.10,12,46,47 These assays (termed “combo” assays”) usually 
do not distinguish antibody reactivity from antigen reactivity. Examples commercially available in 
the United States as of May 2014 include one HIV-1/HIV-2 enzyme immunoassay, one HIV-1/HIV-2 
chemiluminescent immunoassay, and one HIV-1/HIV-2 rapid test that uses separate indicators for 
antigen and antibody reactivity. 
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Laboratory markers of HIV infection and their detection by diagnostic tests 
Analyses of specimens from seroconversion panels have established the dynamics of HIV-1 
viremia after infection and the sequential appearance of different laboratory markers. The 
approximate time at which different markers appear, estimated from different data sources, are 
outlined schematically in Figure 1.48-50  
Immediately after HIV infection, low levels of HIV-1 RNA (ribonucleic acid) might be present 
intermittently, but no viral markers are consistently detectable in plasma.51 Approximately 10 
days after infection, HIV-1 RNA becomes detectable by NAT in plasma and quantities increase 
to very high levels.52-56 Next, HIV-1 p24 antigen is expressed and quantities rise to levels that 
can be detected by 4th generation immunoassays within 4 to 10 days after the initial detection of 
HIV-1 RNA.46,48 However, p24 antigen detection is transient because, as antibodies begin to 
develop, they bind to the p24 antigen and form immune complexes that interfere with p24 assay 
detection unless the assay includes steps to disrupt the antigen-antibody complexes.57-60 Next, 
immunoglobulin (Ig) M antibodies are expressed which can be detected by 3rd and 4th 
generation immunoassays 3 to 5 days after p24 antigen is first detectable, 10 to 13 days after the 
appearance of viral RNA.46,48,49,61 Finally, IgG antibodies emerge and persist throughout the 
course of HIV infection. First and second generation immunoassays designed to detect only IgG 
antibodies exhibit considerable variability in their sensitivity during early infection, becoming 
reactive 18 to 38 days or more after the initial detection of viral RNA.46,48,49,62,63  
The pattern of emergence of laboratory markers is highly consistent and allows classification of 
HIV infection into distinct laboratory stages48,64:  
• The eclipse period is the initial interval after infection with HIV when no laboratory 
markers are consistently detectable.  
• The seroconversion window period is the interval between infection with HIV and the 
first detection of antibodies. Its duration depends on the design of the antibody 
immunoassay and the sensitivity of the immunoassay during seroconversion. 
• Acute HIV infection is the interval between the appearance of detectable HIV RNA and 
the first detection of antibodies. Its duration also depends on the design of the antibody 
immunoassay and the sensitivity of the immunoassay during seroconversion. 
• Established HIV infection is the stage characterized by a fully developed IgG antibody 
response sufficient to meet the interpretive criteria for a positive Western blot or 
IFA.1,61,65  
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Figure 1.  Sequence of appearance of laboratory markers for HIV-1 infection  
 
Note. Units for vertical axis are not noted because their magnitude differs for RNA, p24 antigen, and antibody. 
Modified from MP Busch, GA Satten (1997)50 with updated data from Fiebig (2003),48 Owen (2008),49 and 
Masciotra (2011, 2013).46,66 
Need for updated recommendations for the laboratory diagnosis of HIV-1 and HIV-2 infection  
The previous algorithm, consisting of a repeatedly reactive immunoassay for HIV antibodies and 
positive HIV-1 Western blot or HIV-1 IFA, has been the gold standard for laboratory diagnosis 
of HIV-1 infection in the United States since 1989. False-positive results from this combination 
are rare.67 HIV-2 infection remains uncommon in the United States, and no definitive criteria 
have been recommended for HIV-2 diagnosis.27 Developments and observations in five areas led 
CDC to update recommendations for the laboratory diagnosis of HIV-1 and HIV-2 infections: 
1. The previous testing algorithm for HIV-1 fails to identify acute HIV-1 infections 
Since 1999, blood screening centers in the United States have used pooled HIV-1 NAT to 
identify acute HIV infection in donors who had nonreactive 3rd generation immunoassay 
results.68 (To reduce costs, multiple specimens are pooled for screening with a single NAT; 
specimens from reactive pools undergo individual NAT to identify the specimen with HIV-1 
RNA.) Among persons seeking HIV testing, programs that used pooled NAT after a nonreactive 
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initial antibody immunoassay result have demonstrated detectable HIV-1 RNA in 2 per 10,000 to 
2 per 1,000 persons, depending on the population tested and the generation of the initial 
immunoassay.4-6,8,16,18 Specimens with nonreactive antibody immunoassay results and reactive 
NAT results that represent acute HIV infection have been described in 4% to 32% of all new 
HIV diagnoses at the time of testing in some populations, especially men who have sex with 
men.4,6,8,10 Retrospective testing of specimens from high-risk persons demonstrated that 3rd 
generation immunoassays were reactive in 20% to 37% of specimens that were HIV-1 Western 
blot-negative but NAT-reactive,69-71 and that 4th generation immunoassays were reactive in 62% 
to 83% of specimens that were NAT-reactive but nonreactive with earlier generation 
immunoassays.71-73  
2. Assays that detect HIV-1 infection earlier are now widely available 
New generations of immunoassays with improved sensitivity for detecting early HIV-1 infection 
can narrow the interval between the time of infection and initial immunoassay reactivity (Box 2, 
Figure 1). In 2006, 74% of U.S. public health laboratories used a 1st or 2nd generation 
immunoassay as the initial test in the previous algorithm.74 In 2012, 92% of public health 
laboratories used a 3rd or 4th generation immunoassay as the initial test in the previous 
algorithm.75 However, these immunoassays become reactive days to weeks before the HIV-1 
Western blot becomes positive.46,49 Using the HIV-1 Western blot for confirmation of these 
immunoassays can produce false-negative results during seroconversion.10,76 
3. The risk of HIV-1 transmission from persons with acute and early infection is much higher than 
that from persons with established infection. 
Extremely high levels of infectious virus become detectable in serum and genital secretions 
during acute HIV-1 infection and persist for 10–12 weeks.77-79 Models based on data from cohort 
studies suggest that the rate of sexual transmission during acute infection is 26 times as high as 
that during established HIV-1 infection.20 Acute HIV-1 infection, despite its short duration, can 
account for 10%–50% of all new HIV-1 transmissions, especially in persons who have multiple 
concurrent sex partners or high rates of partner change.19,21,22,80 
4. Initiation of antiretroviral therapy (ART) during the early stage of HIV-1 infection can benefit 
patients and reduce HIV transmission 
Treatment of acute and early HIV-1 infection with combination ART improves laboratory 
markers of disease progression.81,82 Limited data also suggest that treatment of acute HIV-1 
infection might decrease the severity of acute disease, lower the viral set point, slow disease 
progression rates in the event therapy is stopped, reduce the size of the viral reservoir, and 
decrease the rate of viral mutation by suppressing viral replication and preserving immune 
function.23-26,83 Because very high levels of virus in blood and genital secretions increase 
infectiousness during and immediately after acute HIV infection, initiating treatment during 
acute infection can also reduce the risk of HIV-1 transmission substantially.23,77,84 In March 
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2012, the U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for 
Adults and Adolescents recommended initiation of ART for all persons with HIV-1 infection to 
reduce the risk of disease progression and to prevent HIV transmission.23 
5. The use of HIV-1 Western blot in the previous algorithm misclassifies the majority of 
HIV-2 infections 
Correct identification of HIV-2 infections is challenging, but accurate diagnosis of HIV-2 is 
clinically important because some antiretroviral agents effective against HIV-1 (including 
nonnucleoside reverse transcriptase inhibitors and some protease inhibitors) are not effective 
against HIV-2.85,86 Considerable serologic cross-reaction occurs between HIV-1 and HIV-2, but 
screening exclusively with tests for HIV-1 antibodies failed to detect 15% to 53% of HIV-2 
infections.49 As of May 2014, all FDA-approved 3rd and 4th generation immunoassays 
incorporate specific antigens to detect antibodies directed against both HIV-1 and HIV-2.87 
When HIV-1/HIV-2 immunoassays are repeatedly reactive, CDC’s previous recommendations 
advised specific testing for HIV-2 for specimens with negative or indeterminate HIV-1 Western 
blot results.2 However, studies published in 2010 and 2011 showed that the HIV-1 Western blot 
was interpreted as positive for HIV-1 in 46% to 85% of specimens from persons found to be 
infected with HIV-2, resulting in incorrect or delayed diagnosis.27-29 The rapid immunoassay 
approved by the FDA in 2013 for use in algorithms to differentiate HIV-1 from HIV-2 antibodies 
correctly classifies the majority of both HIV-1 and HIV-2 infections in antibody-positive 
specimens, including the subset misclassified as HIV-1 by the HIV-1 Western blot.28,29,47,76,88  
F. Process for Developing Updated Recommendations 
These updated recommendations are the product of a lengthy, multistep process. In 2004, CDC 
and APHL established an HIV Steering Committee --composed of CDC and public health 
laboratory scientists with expertise in HIV diagnostics-- to monitor HIV testing practices, 
investigate reports of problems with the performance or availability of HIV testing reagents, and 
assess potential implications of new assays as they received FDA approval. When the 
shortcomings of previous HIV testing recommendations became evident,5,9,16,18 the HIV Steering 
Committee organized a working group in August 2006 with representatives from CDC, APHL, 
FDA, the National Alliance of State and Territorial AIDS Directors (NASTAD), HIV testing 
program managers, and scientists from academic, hospital, and commercial laboratories and 
blood donor screening programs who had expertise in HIV, immunology, laboratory medicine, 
and evaluation of diagnostic tests (Appendix 1). The Steering Committee asked the working 
group to examine the evidence for the performance of HIV assays and the previous algorithm for 
laboratory HIV diagnosis and to propose new algorithms for HIV diagnosis that maximized 
accuracy, relied on FDA-approved tests, and considered testing costs and cost-effectiveness. A 
subset of this working group served as the writing group that drafted these recommendations 
(Appendix 1). 
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The working group sought assistance from CDC laboratory scientists, who evaluated the 
performance of available FDA-approved assays on panels of plasma specimens from HIV-
infected and uninfected persons and on sequential specimens from persons early in 
seroconversion; analyzed test combinations in two-test and three-test algorithms; and compared 
these results to results of the 1989 algorithm for HIV-1 diagnosis. The working group conducted 
a nonsystematic literature review on the performance characteristics of HIV tests and their use in 
combinations for HIV-1 diagnosis and examined unpublished data generated by studies at CDC 
and other public health laboratories. Based on the information from the literature review, 
unpublished data, and expert opinion, the working group proposed several candidate HIV 
diagnostic algorithms, disseminated descriptions of the candidate algorithms, and solicited data 
evaluating the algorithms in the call for abstracts for the 2007 HIV Diagnostics Conference.89 
New research findings were presented and discussed at the conference, and the working group 
obtained oral comments during the closing session of the conference about the feasibility, 
benefits, harms, and costs of new testing strategies from conference attendees, who included 
managers and staff members from public health department HIV testing programs and scientists 
from clinical, commercial, and public health laboratories, blood donation programs, and 
manufacturers of HIV tests and testing equipment.  
Based on the literature review, expert opinion, and new research findings presented at the 2007 
HIV Diagnostics Conference,89 including CDC’s analysis of the relative sensitivity during 
seroconversion of FDA-approved immunoassays compared with the HIV-1 Western blot,49 the 
working group developed a synopsis, HIV Testing Algorithms: A Status Report,90 issued in April 
2009, that described the candidate algorithms and their limitations. The report outlined the key 
elements of each candidate algorithm, available performance data, potential benefits and 
drawbacks, and additional data needed to substantiate and refine the algorithm. In that report, the 
working group acknowledged that none of the candidate algorithms offered a distinct advantage 
over previous recommendations. For example, performing NAT after all nonreactive antibody 
test results could detect acute HIV-1 infection, but its routine use would be impractical and 
costly. Additionally, most algorithms still included the HIV-1 Western blot and could not 
consistently detect acute HIV-1 infections or HIV-2 infections without the collection of 
demographic, behavioral, or clinical information that might suggest the need for additional 
testing. Moreover, new tests such as 4th generation assays were nearing commercialization, and 
their routine use could render the candidate algorithms obsolete.  
In July 2009, the HIV Steering Committee solicited additional data on the performance of 
candidate algorithms and 4th generation immunoassays in the call for abstracts for the 2010 HIV 
Diagnostics Conference.91 At the March 2010 conference, representatives from the American 
Society for Microbiology, the College of American Pathologists, the Department of Defense, 
FDA, NASTAD, the Pan American Society for Clinical Virology, public health department HIV 
testing programs, and scientists from clinical, commercial, and public health laboratories, blood 
donation programs, and the diagnostics industry reviewed and discussed the research findings 
and their implications for new testing algorithms. (Manuscripts from conference presentations 
 Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations  Published June 27, 2014 15 
were submitted for peer review and published in the December 2011 supplement to the Journal 
of Clinical Virology.92) Based on expert opinion, new data presented at the conference (including 
evidence for misclassification of HIV-2 infections by the HIV-1 Western blot), and anticipation 
of commercialization of 4th generation immunoassays in the United States, CDC and APHL 
laboratory experts proposed a new diagnostic algorithm. The algorithm included 4th generation 
HIV-1/HIV-2 antigen/antibody combination immunoassays (approved by FDA in 2010 and 
2011) and an HIV-1/HIV-2 antibody differentiation assay. The proposed algorithm was intended 
to improve the accurate diagnosis of acute HIV-1 infection and HIV-2 infection in the absence of 
clinical, behavioral, or demographic information that is not routinely available to laboratories.93  
To validate the proposed algorithm for supplemental testing, CDC and public health laboratories 
retrospectively applied available existing test results in the sequence specified by the proposed 
algorithm29,70,76,94 and evaluated the 4th generation immunoassays and proposed algorithm on the 
same specimen collections that had been tested previously.46,66 The HIV Steering Committee 
then used the call for abstracts for the 2012 HIV Diagnostics Conference to solicit additional 
data on the performance of new tests and the proposed algorithm. Three CDC writing group 
members (Branson, Owen, Wesolowski) developed a figure and draft statements for 
consideration during the conference describing the proposed algorithm and possible variations if 
different assays were substituted for those in the proposed algorithm.95 CDC writing group 
members solicited oral comments on the proposed algorithm from stakeholders who attended the 
December 2012 HIV Diagnostics Conference, representing commercial and public health 
laboratories that conduct HIV testing, HIV testing programs, manufacturers of HIV tests and 
testing equipment, providers of HIV clinical and preventive services, and persons with HIV.96 
Their input on the proposed algorithm was informed by conference presentations that compared 
the performance, cost, and cost-effectiveness of the proposed algorithm with the previous 
algorithm and alternatives.97-99 Manuscripts from conference presentations were submitted for 
peer review and published in the December 2013 supplement to the Journal of Clinical 
Virology.100 CDC writing group members also solicited oral comments on the proposed 
algorithm from other stakeholders at meetings of the CDC-HRSA Advisory Committee, 
American Association of Clinical Chemistry, Association of Medical Laboratory Immunologists, 
College of American Pathologists, and the Pan American Society for Clinical Virology. After 
stakeholders expressed support for the proposed recommendations, the writing group finalized 
the recommendations. The draft recommendations and their underlying evidence were then 
reviewed by three independent HIV testing experts not involved in development of the 
recommendations (in accordance with Office of Management and Budget Regulations for peer 
review of influential scientific information from the federal government101) and by officials at 
CDC, the FDA, and the Department of Health and Human Services.  
G. Literature Reviews and Key Questions 
The CDC/APHL working group members conducted a nonsystematic review of the literature, 
unpublished data, meeting abstracts and presentations, and manufacturers’ package inserts in 
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2009 to assess the performance of FDA-approved HIV diagnostic assays and their use in 
combination for the laboratory diagnosis of acute and established HIV-1 infection. Three CDC 
writing group members (Branson, Owen, Wesolowski) updated this with a systematic literature 
review in 2013 focused on 10 key questions: 
1. What is the sensitivity of individual assays in specimens from persons  
a. with established HIV-1 and established HIV-2 infection? 
b. with acute HIV-1 infection? 
2. What is the specificity of individual assays in specimens from uninfected persons? 
3. What is the accuracy of the previous and recommended algorithms based on 
combinations of assays in specimens from persons  
a. with established HIV-1 infection? 
b. with acute HIV-1 infection? 
c. with established HIV-2 infection? 
d. not infected with HIV-1 or HIV-2? 
4. What algorithm(s) requires the minimum number of assays to maximize the accuracy of 
the laboratory diagnosis of HIV-1 infection and HIV-2 infection and minimize the 
number of specimens with indeterminate or inconclusive test results? 
5. Do the costs and cost-effectiveness of the proposed algorithm for the diagnosis of HIV 
infection differ from the costs and cost-effectiveness of the previous algorithm? 
6. Do benefits and harms for patients associated with the proposed diagnostic algorithm 
differ from benefits and harms associated with the previous diagnostic algorithm? 
Three CDC writing group members who reviewed the evidence used the following definitions 
and reference criteria for evaluation of study outcomes:  
• Established HIV-1 infection: repeatedly reactive immunoassay results and positive HIV-1 
Western blot or HIV-1 IFA result 
• Acute HIV-1 infection: reactive HIV-1 NAT result and negative or indeterminate HIV-1 
antibody immunoassay, HIV-1 Western blot, or HIV-1 IFA result 
• False-positive immunoassay result: repeatedly reactive immunoassay results, negative or 
indeterminate HIV-1 Western blot or HIV-1 IFA result, negative HIV-1 NAT result, and 
negative HIV-2 test results 
• False-negative immunoassay result: nonreactive immunoassay result and reactive HIV-1 
NAT result 
• False-negative NAT result: repeatedly reactive immunoassay results, positive HIV-1 
Western blot result and negative HIV-1 NAT result 
• Established HIV-2 infection: expert interpretation based on the results of tests described 
in each study (because no definitive diagnostic algorithm and no FDA-approved test for 
confirming the presence of HIV-2 infection existed as of May 2014) 
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• Accuracy of algorithms: the number or percentage of all specimens from a given 
algorithm that, based on all available test results and follow-up information, yielded a 
correct laboratory diagnosis of HIV-1 infection, HIV-2 infection, or the absence of HIV 
infection. True-positive and true-negative results were classified as correct laboratory 
diagnoses. False-negative, false-positive, and indeterminate results, and HIV-2 infections 
misclassified as HIV-1 were classified as incorrect laboratory diagnoses. 
Appendix 2 provides details of the search strategy and a detailed summary and tables of evidence 
for the published studies relevant to the key questions. 
H. Recommendations for Laboratory Testing for the Diagnosis of HIV Infection 
CDC and APHL recommend that laboratories conduct the following sequence of assays with 
serum or plasma specimens for the accurate diagnosis of HIV infection. Each recommendation 
lists the rationale for the recommendation and refers to additional evidence and limitations in the 
corresponding summary and tables of evidence in Appendix 2. These updated recommendations 
for testing of serum or plasma specimens supersede the 1989 recommendations for interpretation 
and use of the HIV-1 Western blot in the serologic diagnosis of HIV Type 1 infections,1 the 1992 
recommendations for testing for antibodies to HIV Type 2 in the United States,2 and the 2004 
recommended protocol for confirmation of rapid HIV tests.3 Because none of the assays in the 
recommended algorithm are FDA-approved for use with oral fluid or dried blood spot 
specimens, these updated recommendations do not supersede previous recommendations for 
testing of dried blood spots or oral fluid for HIV-1 using the FDA-approved immunoassay and 
HIV-1 Western blot for these specimen types.1 
1. Laboratories should conduct initial testing for HIV with an FDA-approved 
antigen/antibody combination (4th generation) immunoassay* that detects HIV-1 and 
HIV-2 antibodies and HIV-1 p24 antigen to screen for established infection with HIV-1 
or HIV-2 and for acute HIV-1 infection. No further testing is required for specimens that 
are nonreactive on the initial immunoassay. 
Rationale: Initial testing with a 4th generation antigen/antibody combination 
immunoassay detects more acute HIV-1 infections than initial testing with a 3rd 
generation antibody immunoassay and identifies comparable numbers of established 
HIV-1 and HIV-2 infections, with comparable specificity.  
Evidence basis (Appendix 2): 1.a.1, 1.a.2, 1.b.1, 2.a, 2.b, 3.a, 3.b, 3.c, 4.a, 4.b, 5 
2. Specimens with a reactive antigen/antibody combination immunoassay result (or 
repeatedly reactive, if repeat testing is recommended by the manufacturer or required by 
regulatory authorities) should be tested with an FDA-approved antibody immunoassay 
                                                            
* Exception: As of April 2014, data are insufficient to recommend use of the FDA-approved single-use rapid HIV-
1/HIV-2 antigen/antibody combination immunoassay as the initial assay in the algorithm. 
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that differentiates HIV-1 antibodies from HIV-2 antibodies. Reactive results on the initial 
antigen/antibody combination immunoassay and the HIV-1/HIV-2 antibody 
differentiation immunoassay should be interpreted as positive for HIV-1 antibodies, HIV-
2 antibodies, or HIV-1 and HIV-2 antibodies, undifferentiated. 
Rationale: Use of the HIV-1/HIV-2 antibody differentiation assay after a reactive initial 
4th generation HIV-1/HIV-2 antibody immunoassay detects HIV-1 antibodies earlier 
than the HIV-1 Western blot, reduces indeterminate results, and identifies HIV-2 
infections. Turnaround time for test results is shorter and the cost is lower for the HIV-
1/HIV-2 antibody differentiation assay compared with the HIV-1 Western blot. 
Available evidence is insufficient to recommend specific additional testing, without 
clinical follow-up, for specimens that are dually reactive for HIV-1 and HIV-2 
antibodies on the differentiation immunoassay (see Section J, Limitations of the 
Recommended Laboratory Testing Algorithm). 
Evidence basis (Appendix 2): 1.a.3, 1.b.2, 2.c, 3.a, 3.c, 3.d, 4.a, 4.b, 4.c, 5, 6 
3. Specimens that are reactive on the initial antigen/antibody combination immunoassay and 
nonreactive or indeterminate on the HIV-1/HIV-2 antibody differentiation immunoassay 
should be tested with an FDA-approved HIV-1 NAT.  
• A reactive HIV-1 NAT result and nonreactive HIV-1/HIV-2 antibody 
differentiation immunoassay result indicates laboratory evidence for acute HIV-1 
infection. 
• A reactive HIV-1 NAT result and indeterminate HIV-1/HIV-2 antibody 
differentiation immunoassay result indicates the presence of HIV-1 antibodies 
confirmed by HIV-1 NAT. 
• A negative HIV-1 NAT result and nonreactive or indeterminate HIV-1/HIV-2 
antibody differentiation assay result indicates a false-positive result on the initial 
immunoassay.†  
Rationale: HIV-1 NAT results can distinguish acute HIV-1 infection from false-
positive initial immunoassay results in specimens with a reactive antigen/antibody 
immunoassay and a nonreactive HIV-1/HIV-2 antibody differentiation assay result. 
HIV-1 NAT does not detect HIV-2, and no HIV-2 NAT is FDA-approved. Available 
evidence is insufficient to recommend testing for acute HIV-2 infection after a 
nonreactive HIV-1 NAT result (see Section K, Limitations of the Evidence Supporting 
These Recommendations).  
Evidence basis: (Appendix 2): 1.b.1, 2.e, 3.b, 3.d, 4.a, 4.b, 5, 6 
                                                            
† See Section M, Additional Considerations, for a discussion of issues related to acute HIV-2 infection. 
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4. Laboratories should use this same testing algorithm, beginning with a laboratory-based 
antigen/antibody combination immunoassay, with serum or plasma specimens submitted 
for testing after a reactive (preliminary positive) result from any rapid HIV test.  
Rationale: Previously, supplemental testing (HIV-1 Western blot or HIV-1 IFA) was 
recommended after a reactive rapid HIV test result regardless of the result of the initial 
laboratory immunoassay. This was based on observations of some false-negative results 
from earlier generations of immunoassays (no longer commercially available in the 
United States) that became reactive later during seroconversion than rapid HIV 
antibody tests.3 With the recommended algorithm, the FDA-approved laboratory-based 
antigen/antibody combination immunoassays detect HIV infection earlier during 
seroconversion than any of the rapid HIV tests available in the United States as of May 
2014, including the rapid HIV-1/HIV-2 antigen/antibody combination test. Therefore, 
no supplemental testing is required for specimens that are nonreactive on the initial 
immunoassay in the recommended algorithm. 
Evidence basis (Appendix 2): 1.a.1, 1.b.1, 4.d  
I. Alternative Testing Sequences When Tests in the Recommended Algorithm Cannot 
be Used 
During their review and comment on these recommendations, stakeholders described 
circumstances that might delay or prevent implementation of some of the assays in the 
recommended algorithm. Based on the evidence review and expert opinion from stakeholders 
and the working group, CDC members of the writing group identified testing sequences that 
might be used to improve the laboratory diagnosis of HIV infection if an alternative FDA-
approved assay is substituted for one of the classes of assays specified in the recommended 
algorithm. Replacing a recommended assay has limitations described below that may reduce the 
accuracy of the testing algorithm. 
• Use of a 3rd generation HIV-1/2 antibody immunoassay instead of a 4th generation 
antigen/antibody combination immunoassay as the initial test: perform subsequent testing 
as specified in the recommended algorithm.  
Limitations: This alternative will miss some acute HIV-1 infections in antibody-
negative persons that would be detected by 4th generation antigen/antibody 
combination immunoassays.  
Supporting evidence (Appendix 2): 1.a.1, 1.a.3, 1.b.1, 1.b.2, 3.a, 3.b, 3.c, 3.d, 4.a, 5, 6 
• Use of the HIV-1 Western blot or HIV-1 IFA as the second test in the algorithm instead 
of an HIV-1/HIV-2 antibody differentiation immunoassay: if test results are negative or 
indeterminate, perform HIV-1 NAT; if HIV-1 NAT is negative, perform HIV-2 antibody 
immunoassay.  
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Limitations: This alternative might misclassify some HIV-2 infections as HIV-1, 
requires a larger number of tests, and increases turnaround time for test results. 
Supporting evidence (Appendix 2): 1.a.3, 1.b.2, 2.c, 3.b, 3.c, 3.d, 4.a, 4.c, 5, 6 
• Use of HIV-1 NAT as the second test instead of an HIV-1/HIV-2 antibody differentiation 
immunoassay: If HIV-1 NAT result is negative, perform an HIV-1/HIV-2 antibody 
differentiation immunoassay or other FDA-approved HIV-1 supplemental antibody test. 
If result of an HIV-1 supplemental antibody test is nonreactive or indeterminate, perform 
an HIV-2 antibody test.  
Limitations: This alternative fails to distinguish acute HIV-1 infection from established 
HIV-1 infection, increases turnaround time for test results and incurs additional costs. 
Supporting Evidence (Appendix 2): 1.a.2, 2.e, 3.b, 4.b, 5, 6 
• Use of HIV-1 NAT (or pooled HIV-1 NAT) after a nonreactive 3rd or 4th generation 
immunoassay result: a reactive NAT result provides evidence of acute HIV-1 infection, 
but false-positive results occur. Follow-up testing to document seroconversion should be 
conducted if a laboratory HIV diagnosis is based on the result of HIV-1 NAT only. 
Limitations: No HIV-1 NAT is FDA-approved for pooled testing for HIV diagnosis. 
Individual or pooled HIV-1 NAT can detect acute infections not detected by a 4th 
generation immunoassay, but occasionally produces a false-positive result, requires 
more tests on each specimen ,increases turnaround time for test results, and is more 
costly than the recommended algorithm.  
Supporting evidence (Appendix 2): 2.e, 4.b, 5, 6 
J. Limitations of the Recommended Laboratory Testing Algorithm 
1. No diagnostic test or algorithm can be completely accurate in all cases of HIV infection. 
Rare instances have been reported of persons who remained persistently negative for 
antibodies despite detectable HIV RNA.102 False-positive HIV test results have been 
attributed to specimen mix-up, mislabeling, and to autoimmune disorders.103-106 
Inconsistent or conflicting test results should be investigated with follow-up testing on a 
newly collected specimen.  
2. A small percentage of specimens produce results that are undifferentiated (dually reactive 
for HIV-1 and HIV-2 antibodies) on the HIV-1/HIV-2 antibody differentiation assay after 
completing all testing procedures recommended by the manufacturer. The frequency of 
dually reactive results on the HIV-1/HIV-2 antibody differentiation assay in the United 
States is unknown and follow-up data are limited. One study reported 5 (0.50%) of 993 
specimens with repeatedly reactive immunoassay results were dually reactive with the 
HIV-1/HIV-2 antibody differentiation assay approved by the FDA as of March 2013.107 
Three specimens with strong HIV-1 reactivity and weak HIV-2 reactivity were negative 
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by HIV-2 immunoblot and positive for all HIV-1 Western blot bands. One specimen with 
strong reactivity for both the HIV-1 and HIV-2 indicators was positive by HIV-2 
immunoblot; HIV-2 RNA was detected and HIV-1 RNA was undetectable. The fifth 
specimen, with weak reactivity for both the HIV-1 and HIV-2 indicators, lacked 
sufficient volume for definitive resolution. The authors concluded that strong reactivity at 
the indicator for HIV-2 suggested the need for more specific HIV-2 testing.107 Published 
data and genotypic analyses from West Africa, where HIV-2 infection is endemic and 
where the largest number of dual HIV-1/HIV-2 infections have been reported, indicate 
that most specimens dually reactive for HIV-1 and HIV-2 antibodies represent HIV-1 
infections with cross-reactivity to HIV-2 antigens.108,109 A single case of dual HIV-
1/HIV-2 infection has been reported in the United States in a patient who reported sexual 
contact with a person from Gambia.110 No other published studies of U.S. populations 
provide evidence to recommend specific additional tests for specimens with dually 
reactive antibody test results. Based on expert opinion, the low prevalence of HIV-2 
infection in the United States, and the lack of an FDA-approved NAT for HIV-2, 
laboratories should report dually reactive test results as positive for HIV antibodies that 
could not be differentiated as HIV-1 or HIV-2, and recommend further investigation for 
HIV-2 if clinically indicated (for example, if HIV-1 RNA is undetectable on the viral 
load assay conducted as part of the initial medical workup). See Section M, Additional 
Considerations, for information related to HIV-2 infection. 
3. None of the assays in the updated recommended algorithm are FDA-approved for use 
with oral fluid or dried blood spot specimens. Laboratories should follow the 1989 
recommendations1 (http://stacks.cdc.gov/view/cdc/7344) for using the HIV-1 
immunoassay and HIV-1 Western blot approved by the FDA for these specimen types. 
4. The recommended algorithm has not been evaluated in persons taking ART for 
preexposure or postexposure prophylaxis. Occurrences of delayed seroconversion have 
been reported in persons taking ART for preexposure111 and postexposure prophylaxis.112 
As of May 2014, data are insufficient to determine whether additional follow-up testing 
might be indicated for persons taking ART. 
5. The recommended algorithm has not been evaluated in specimens from persons with 
long-term HIV suppression from antiretroviral therapy. Studies document that antibody 
levels diminish, some immunoassays become nonreactive, and the HIV-1 Western blot 
reverts from positive to indeterminate in a small percentage of patients who maintain 
undetectable levels of HIV, especially after antiretroviral therapy initiated early during 
the acute phase of infection.113-116 It has been postulated that rapid and effective virologic 
suppression due to potent, early antiretroviral therapy may result in levels of antigenic 
stimulation that are inadequate for developing and maintaining HIV- 1-specific antibody 
responses.115 Although one study demonstrated the FDA-approved HIV-1/HIV-2 
antibody differentiation assay remained reactive in patients with various levels of 
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exposure to antiretroviral therapy,117 as of May 2014, data are insufficient to determine 
whether the recommended algorithm might produce false-negative results with specimens 
from persons taking antiretroviral therapy who have maintained long-term viral 
suppression.  
6. The recommended algorithm increases the ability to detect acute HIV-1 infection, but no 
laboratory assay can detect HIV infection immediately after it is acquired. The duration 
of the eclipse period between infection and the appearance of HIV RNA is not well-
defined from clinical studies and likely varies with the infection route, inoculum size, and 
sensitivity of the NAT used to detect HIV-1 nucleic acids. 
K. Limitations of the Evidence Supporting These Recommendations  
1. Evaluations of test performance were based on comparison with a composite standard for 
the presence of HIV infection that consisted of a positive HIV-1 Western blot, the 
presence of HIV-1 RNA, or both. Clinical evidence from follow-up evaluations was 
rarely available to document true HIV status (for example, antibody seroconversion after 
a specimen reactive only for HIV-1 NAT, or the subsequent detection of HIV-1 RNA in 
specimens that were classified as positive for HIV-1 antibody by the HIV-1/HIV-2 
differentiation assay). Therefore, it is possible that some false-positive test results might 
have gone undetected in the performance evaluations. 
2. Only two HIV-1/HIV-2 antigen/antibody combination immunoassays, one HIV-1/HIV-2 
antibody differentiation immunoassay, and one HIV-1 NAT were approved by the FDA 
for HIV diagnosis as of December 2012 (Appendix 2, Table 2). All performance 
evaluations of the recommended diagnostic testing algorithm were conducted with these 
assays. Additional evaluations will be required with new assays as they are introduced 
and receive FDA approval. 
3. Published studies document indeterminate results (reactivity to only the synthetic gp41 
peptide or recombinant gp41 protein, but not both) in 0.8% to 1.4% of specimens with 
reactivity on the FDA-approved HIV-1/HIV-2 antibody differentiation immunoassay; 
11% to 15% of specimens with indeterminate results proved to be HIV-negative.76,118 No 
published data from follow-up testing are available to definitively determine whether 
indeterminate results in specimens with detectable HIV-1 RNA represent an evolving 
antibody response consistent with antibody development during acute infection or 
whether indeterminate results might persist during established infection in some persons. 
4. Little evidence exists for the timing of antibody development after infection with HIV-2 
or the occurrence of acute HIV-2 infection in the United States, and no HIV-2 NAT is 
FDA-approved. The 4th generation antigen/antibody combination assays detect IgM and 
IgG antibodies against both HIV-1 and HIV-2 and also p24 antigen, specific for HIV-1, 
but not p26/27, the counterpart core protein in HIV-2.66 The HIV-1/HIV-2 antibody 
differentiation assay detects only IgG antibodies against HIV-1 and HIV-2. Therefore, it 
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is possible that IgM antibodies against HIV-2 might have been present in a small number 
of specimens with a repeatedly reactive 4th generation immunoassay result that were 
classified as HIV-negative on the basis of a nonreactive HIV-1/HIV-2 antibody 
differentiation assay result and negative HIV-1 NAT. See Section M, Additional 
Considerations, for a discussion of issues related to acute HIV-2 infection. 
5. Rare cases of a “second window” during early seroconversion during which 
antigen/antibody combination tests transiently revert to nonreactive have been reported 
outside the United States with older versions of 4th generation tests than those that are 
FDA-approved.119-121 One case of a “second window” of 8 days’ duration was observed 
in a study of 28 patients in Africa and Thailand with acute, non-B subtype HIV infections 
identified by frequent RNA testing.122 Subsequent testing was conducted with 
immunoassays and viral load assays at frequent intervals. In this case, an FDA-approved 
4th generation assay became reactive for antigen at day 9 after RNA detection, was 
subsequently nonreactive between days 17-25, and became reactive again at day 29 when 
antibody levels, detected by a 3rd generation assay, began to rise. Presumably, this 
phenomenon was due to the short interval when antibodies begin to appear during which 
antigen bound to antibody inhibits detection of either antigen or antibody by the assays. 
Experience with the FDA-approved 4th generation immunoassays is too limited to 
predict whether or how often transient seroreversion might occur in patients with subtype 
B infections. 
L. How These Updated Recommendations Differ From Previous Recommendations 
Compared with previous testing recommendations, the updated algorithm increases sensitivity 
for acute HIV-1 infection by including an initial immunoassay that detects antibodies to both 
HIV-1 and HIV-2 and also HIV-1 p24 antigen, which can be detected before antibodies develop. 
The updated algorithm identifies acute HIV-1 infection by using HIV-1 NAT for specimens that 
are reactive on the initial immunoassay but negative for antibodies on the second immunoassay.  
The previously recommended HIV testing algorithms were predicated on screening for HIV-1 
antibodies;1 specific testing for HIV-2 antibodies was confined to only limited circumstances.2 
The updated algorithm screens for both HIV-1 and HIV-2 antibodies, and distinguishes HIV-1 
from HIV-2 antibodies using a single supplemental antibody differentiation immunoassay. This 
diagnostic approach is simpler and more accurate than CDC’s 1992 recommendations because it 
no longer depends on laboratory access to clinical, demographic or behavioral information 
suggestive of possible HIV-2 exposure. Because the recommended algorithm no longer relies on 
HIV-1 Western blot or HIV-1 IFA as a supplemental test, it yields fewer specimens with 
indeterminate results that require resolution by a follow-up test conducted several months later. 
Previously, supplemental testing with HIV-1 Western blot or HIV-1 IFA was recommended for 
all specimens submitted for testing after a reactive rapid HIV test result even if the initial 
laboratory immunoassay was nonreactive. With the updated recommendation, specimens 
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submitted after any reactive rapid HIV test result (including the HIV-1/HIV-2 antibody 
differentiation assay, when it is used as an initial rapid test, and the HIV-1/HIV-2 
antigen/antibody combination rapid test) are tested according to the same algorithm as all other 
specimens. No further supplemental testing is required if the result of the initial antigen/antibody 
combination immunoassay is nonreactive. 
M. Additional Considerations  
Medical evaluation and follow-up testing. A laboratory diagnosis of HIV infection identifies the 
need for HIV medical care. Rarely, specimen mix-up or unexplained cross-reactivity may result 
in an incorrect laboratory diagnosis with either the previous or the recommended algorithm.76,123 
The Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults 
and Adolescents recommends a baseline evaluation for every HIV-infected patient entering into 
care, with a complete medical history, physical examination, and laboratory evaluation, 
including plasma HIV-1 RNA viral load, CD4 determination, and an antiretroviral resistance 
assay, to confirm the presence of HIV infection, stage HIV disease, and assist in the selection of 
an initial antiretroviral drug regimen.23 If HIV-1 RNA is below the assay’s limit of detection, 
repeat or additional testing is indicated to verify the diagnosis of HIV infection.  
Participants in HIV vaccine trials. Recipients of HIV vaccines might have vaccine-induced 
antibodies that produce reactive HIV antibody test results.124 Laboratories should advise persons 
who order HIV testing that vaccine recipients with reactive immunoassay results should be 
encouraged to contact a vaccine trial site for specialized testing necessary to determine their HIV 
infection status.125  
HIV-2 infection. Fewer than 200 cases of HIV-2 in the United States had been reported to CDC 
through 2009,27 although criteria for an HIV-2 case definition were not specified until 2014.126 
The majority of HIV-2 diagnoses in the United States have been made in persons born in Africa, 
especially West Africa, but 12% of HIV-2 diagnoses were made in persons whose birthplace was 
India, North America or Europe.27,28 It is theoretically possible that acute HIV-2 infection might 
produce a repeatedly reactive HIV-1/HIV-2 antigen/antibody combination immunoassay result 
with nonreactive HIV-1/HIV-2 antibody differentiation assay and HIV-1 NAT results. Based on 
expert opinion and the low prevalence of HIV-2 infection in the United States, this sequence of 
test results most likely indicates a false-positive initial immunoassay result. Laboratories should 
report that such test results indicate no laboratory evidence for HIV-1 infection and suggest 
follow-up testing for HIV-2 if clinically indicated. Although accurate diagnosis of HIV-2 is 
clinically important because HIV-2 strains are naturally resistant to several antiretroviral drugs 
developed to suppress HIV-1,127 diagnosis of HIV-2 can be problematic. Only two reports of 
acute HIV-2 infections have been published; both occurred in West Africa and were documented 
by seroconversion.128,129 The reliability of HIV-2 NAT during acute HIV-2 infection is unknown. 
In specimens obtained 5 to 6 months after seroconversion, plasma HIV-2 viral load was 28 times 
lower in HIV-2 seroconverters than among comparable HIV-1 seroconverters.130  
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Because HIV-2 RNA is undetectable in at least half of HIV-2 infected patients, testing for 
proviral DNA may be required for definitive diagnosis.131,132 No tests for HIV-2 RNA or DNA 
have received FDA approval. If additional testing for HIV-2 is requested, HIV-2 NAT for which 
the analytic performance characteristics have been determined may be available from 
commercial laboratories, city or state public health laboratories, or CDC.28,133,134  
Specimen collection and storage requirements. Freshly collected serum or plasma specimens 
yield the most accurate HIV test results. Specimen volume also influences the ability to perform 
the recommended algorithm because a larger volume is needed for specimens that require testing 
by both the HIV-1/HIV-2 differentiation immunoassay and HIV-1 NAT. A venipuncture 
specimen of at least 5 ml of whole blood is necessary to yield at least 2 ml of serum or plasma 
needed to conduct all assays in the recommended algorithm. Some laboratories require a separate 
specimen for NAT. Specific assays that can be used in the recommended algorithm have 
different requirements for specimen collection, storage temperatures, and the need for or timing 
of separating cells from serum or plasma. These requirements are specified by the manufacturer 
and sometimes change. Ensuring accurate results requires that laboratories 
• carefully review manufacturer’s instructions in each assay’s package insert to determine 
requirements for acceptable specimen types (serum, plasma), volume, collection tubes, 
anticoagulants, cell separation, storage and shipping requirements, and timeframes 
(keeping in mind that these include shipping periods) 
• communicate these specific requirements to the persons who submit specimens for 
testing  
• request collection of another specimen from a second venipuncture if all tests cannot be 
performed on the same specimen 
• confirm handling, storage, and shipping requirements before sending specimens to 
reference laboratories for additional testing 
N. Reporting Results of the Recommended Algorithm for the Laboratory Diagnosis of 
HIV 
Laboratory practices for reporting test results and providing interpretation of results to the 
persons who ordered the HIV test are influenced by  
• the assay manufacturer’s instructions (specified in product inserts), 
• guidance or recommendations from regulatory or scientific agencies and professional 
associations, 
• local clinical practice needs (communicated through requests from institutional clinical 
practice committees), 
• requirements of the laboratory information system, and 
• requirements of the electronic health record. 
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Table 1 summarizes suggested interpretations for reporting each potential outcome of the 
recommended testing algorithm to persons ordering the HIV test and to health department 
surveillance programs, adapted from those developed by the New York State Clinical Laboratory 
Evaluation Program.135 Additional suggestions for reporting HIV test results are available from 
APHL at http://stacks.cdc.gov/view/cdc/22423 and from the Clinical Laboratory Standards 
Institute.136  
Reporting HIV test results to persons who ordered HIV testing 
Laboratory experts identified several elements of reports of test results and interpretation that can 
help guide persons who ordered the HIV test and avoid interpretive errors. Reports to persons 
who ordered HIV testing should specify 
• all assays that were used 
• the results of each assay 
• interpretation of the results  
• any additional testing that is recommended using existing specimens or new specimens 
that should be submitted 
• if alternatives to the recommended assays or algorithm sequence were used, the assays 
that were used and limitations of these tests or sequence compared with the 
recommended algorithm 
Laboratories should report final results when all testing is complete, but can also report test 
results of individual assays used in the algorithm as they become available. If results of all tests 
are not reported at one time, the report should specify which test results are pending. 
Laboratories should establish methods to expedite reporting of test results consistent with acute 
HIV infection to the person who ordered HIV testing and to public health authorities to facilitate 
prompt notification and provision of services for acutely infected persons and their sex and drug 
injection partners. 
Reporting HIV test results to public health authorities 
All states, the District of Columbia, and United States territories and dependent areas require that 
laboratories report test results indicative of HIV infection to public health authorities in the 
patient’s jurisdiction of residence.137 Table 1 lists suggested elements that should be reported to 
public health authorities for each potential outcome of the recommended algorithm. However, 
specific requirements of state or local health departments might differ. The following reporting 
principles will facilitate accurate case reporting:  
1. Results from the recommended laboratory testing algorithm with a negative overall 
conclusion (i.e., indicating that the patient is uninfected) should not be reported.  
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2. If the conclusion of the laboratory diagnostic testing algorithm is positive, indicating the 
presence of HIV infection, laboratories should report, in the same data transmission to the 
public health authorities: 
a. the overall result or conclusion of the lab algorithm, and 
b. results from each test performed (including negative/nonreactive or indeterminate 
results)  
3. If the recommended laboratory diagnostic testing algorithm was not completed and the 
overall conclusion was not determined (indicating possible HIV infection that requires 
additional testing or follow-up), the laboratory should follow local requirements for 
reporting incomplete or inconclusive results. 
O. Plans for Updating These Recommendations 
Anticipating continued improvements in laboratory diagnostic techniques, CDC will monitor the 
introduction and FDA approval of diagnostic assays for HIV infection and update these 
recommendations when necessary. CDC’s Division of HIV/AIDS Prevention in the National 
Center for HIV, Viral Hepatitis, STD, and TB Prevention, with APHL, will continue to monitor 
the performance of the laboratory testing algorithm and review the performance of the 
recommended algorithm at least every five years.  
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Table 1. Reporting results from the HIV diagnostic testing algorithm to persons ordering HIV tests and public health authorities 
Adapted from Interim Guidelines for Laboratories on the Use of a New Diagnostic Testing Algorithm for Human Immunodeficiency Virus (HIV) Infection. New York State 
Department of Health.135  
Test performed Test results Final interpretation for provider report 
Test results to be reported 
to public health authorities 
1. HIV-1/2 Ag/Ab combination immunoassay 1. Nonreactive Negative for HIV-1 antigen and HIV-1/HIV-2 antibodies. No 
laboratory evidence of HIV infection. If acute HIV infection is 
suspected, consider testing for HIV-1 RNA. 
Reporting this test result is not 
required. 
1. HIV-1/2 Ag/Ab combination immunoassay 
2. HIV-1/HIV-2 antibody differentiation immunoassay 
1. Reactive 
2. HIV-1 reactive and HIV-2 nonreactive 
Positive for HIV-1 antibodies. Laboratory evidence consistent 
with established HIV-1 infection is present. 
Report test results 1 and 2. 
1. HIV-1/2 Ag/Ab combo immunoassay 
2. HIV-1/HIV-2 antibody differentiation immunoassay 
1. Reactive 
2. HIV-1 nonreactive and HIV-2 reactive 
Positive for HIV-2 antibodies. Laboratory evidence of HIV-2 
infection is present. 
Report test results 1 and 2. 
1. HIV-1/2 Ag/Ab combination immunoassay 
2. HIV-1/HIV-2 antibody differentiation immunoassay 
3. HIV-1 RNA assay 
1. Reactive 
2. Nonreactive or indeterminate 
3. RNA not detected 
HIV antibodies were not confirmed and HIV-1 RNA was not 
detected. No laboratory evidence of HIV-1 infection. Follow-up 
testing for HIV-2 should be performed if clinically indicated.  
Reporting this test result is not 
required. 
1. HIV-1/2 Ag/Ab combination immunoassay 
2. HIV-1/HIV-2 antibody differentiation immunoassay 
3. HIV-1 RNA assay 
1. Reactive 
2. Nonreactive 
3. RNA detected 
Positive for HIV-1. Laboratory evidence consistent with acute 
HIV-1 infection is present. 
Report test results 1, 2, and 3. 
1. HIV-1/2 Ag/Ab combination immunoassay 
2. HIV-1/HIV-2 antibody differentiation immunoassay 
3. HIV-1 RNA assay 
1. Reactive 
2. Indeterminate 
3. RNA detected 
Positive for HIV-1 antibodies. Laboratory evidence of HIV-1 
infection confirmed by HIV-1 RNA. 
Report test results 1, 2, and 3. 
1. HIV-1/2 Ag/Ab combination immunoassay 
2. HIV-1/HIV-2 antibody differentiation immunoassay 
1. Reactive 
2. HIV-1 and HIV-2 reactive  
Positive for HIV antibodies. Laboratory evidence of HIV 
infection is present. HIV antibodies could not be differentiated 
as HIV-1 or HIV-2. Additional testing for HIV-1 RNA or HIV-2 
RNA should be performed if clinically indicated. 
Report test results 1 and 2. 
1. HIV-1/2 Ag/Ab combination immunoassay 
2. HIV-1/HIV-2 antibody differentiation immunoassay 
1. Reactive 
2. Nonreactive or indeterminate 
HIV-1 antibodies were not confirmed and HIV-1 RNA testing 
was not performed. Testing of this specimen is incomplete. 
Follow-up testing for HIV antibodies and HIV-1 RNA is 
recommended as soon as possible. 
Report test results 1 and 2. 
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Appendix 2. 
Analytic Framework, Search Strategy, and Summary of Evidence  
A. Analytic Framework  
Three CDC writing group members (Branson, Owen, Wesolowski) identified key questions and 
conducted a systematic literature review to compare outcomes of the previous and proposed 
algorithm recommendations based on the premise that an accurate HIV test result constituted an 
outcome important to patients.138,139 The CDC working group members evaluated the evidence 
using criteria adapted to the types of study designs necessary to answer the key questions and an 
analytic framework that links the key questions to outcomes related to the performance of 
individual assays and their use in combinations (Figure 2).  
The evidence synthesis focused on the relative effects of the previous and recommended testing 
algorithms on diagnostic accuracy and yield. The CDC reviewers considered tests or algorithms 
that classified specimens as true-positive or true-negative for HIV-1 or HIV-2 as benefits to 
patients and being classified as false-positive or false-negative or receiving indeterminate or 
inconclusive results as harms. They considered reduced turnaround time as a benefit, and 
delayed diagnosis due to the need for additional specimens or follow-up testing as a 
harm.42,139,140 Services after diagnosis for persons with HIV and for those identified as uninfected 
would be needed regardless of which testing algorithm is used.  
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Figure 2. Analytic Framework: Laboratory Testing for Accurate Diagnosis of HIV Infection  
 
Key Questions:  
1a. What is the sensitivity of individual assays in specimens from persons with established 
HIV-1 and HIV-2 infection? 
1b. What is the sensitivity of individual assays in specimens from persons with acute HIV-1 
infection? 
2. What is the specificity of individual assays in specimens from uninfected persons?  
3a. What is the accuracy of algorithms based on combinations of assays in specimens from 
persons with established HIV-1 infection?  
3b. What is the accuracy of algorithms based on combinations of assays in specimens from 
persons with acute HIV-1 infection?  
3c. What is the accuracy of algorithms based on combinations of assays in specimens from 
persons with established HIV-2 infection?  
3d. What is the accuracy of algorithms based on combinations of assays in specimens from 
persons not infected with HIV?  
4. What algorithm(s) required the fewest number of assays to maximize accuracy and 
minimize indeterminate or inconclusive test results?  
5. Do the costs and cost-effectiveness of the proposed algorithm for the diagnosis of HIV 
infection differ from the costs and cost-effectiveness of the previous algorithm?  
6. Do benefits and harms for patients associated with the proposed diagnostic algorithm 
differ from benefits and harms associated with the previous diagnostic algorithm? 
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B. Strategy for Searching Published Literature and Conference Abstracts 
CDC writing group members conducted literature searches in PubMed, in abstracts and 
presentations from the Conferences on Retroviruses and Opportunistic Infections, and in 
abstracts and presentations from the 2007, 2010, and 2012 HIV Diagnostics Conferences 
(available at http://hivtestingconference.org). They also consulted data submitted to the FDA and 
published in the manufacturers’ FDA-approved package inserts. The writing group evaluated 
only studies reported in English and conducted with specimens from U.S. populations, except for 
questions related to HIV-2. Studies that reported results for assays that were not approved or 
under consideration by the FDA were excluded. 
CDC writing group members conducted the literature search using the terms HIV, HIV-1, and 
HIV-2 in combination with antibody assay, antigen/antibody combination assay, acute HIV 
infection, testing, clinical diagnostics, serologic tests, third generation assay, fourth generation 
assay, p24 antigen, seroconversion, indeterminate, false-positive, false-negative, nucleic acid 
test, nucleic acid amplification test, RNA assay, Western blot, costs, and cost-effectiveness. CDC 
writing group members identified additional published reports by examining references listed in 
the retrieved articles. Only studies published or accepted for publication from January 2000 
through December 2013 that evaluated laboratory assays approved by the FDA as of December 
2012 (Table 2) were included in the evidence synthesis.  
The literature search identified 1,858 abstracts of potentially relevant articles. Of these, 1,778 
were excluded because they were background articles, did not contain assay performance data, or 
evaluated assays that were not FDA-approved. Of the remaining 80, 39 articles contained data 
relevant to the key questions for evaluating individual assays or diagnostic algorithms for HIV; 4 
studies related to costs or cost-effectiveness; 2 studies related to potential harms from 
indeterminate HIV test results; 14 studies described viral dynamics of HIV and generic 
laboratory markers without identifying specific assays; 6 studies described HIV-2 distribution 
and diagnosis with assays that are not FDA-approved; 3 studies evaluated HIV-1 diagnosis in 
infants; 7 studies modeled transmission attributable to acute HIV-1 infection; and 5 studies 
evaluated the potential benefits of antiretroviral therapy for acute HIV-1 infection. 
Each of the three CDC writing group members experienced with HIV diagnostic testing studies 
reviewed the studies independently. For each study, one member abstracted details about the 
study design, source of specimens, assays evaluated, and study results. Another one of the three 
CDC writing group members reviewed data abstraction for accuracy. Discrepancies regarding 
the applicability of the evidence or limitations of the studies were resolved by consensus. 
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Table 2. FDA-approved assays included in evidence synthesis 
Assay class 
Trade name 
(Manufacturer) 
Abbreviation used in 
evidence tables 
HIV-1/HIV/2 immunoassay 
“3rd generation” 
Advia Centaur HIV 1/O/2 Enhanced 
(Siemens Healthcare Diagnostics, Malvern, PA) 
Advia  
GS HIV-1/HIV-2 PLUS O EIA 
(Bio-Rad Laboratories, Redmond, WA) 
GS Plus O 
Vitros Anti-HIV 1+2 Assay 
(Ortho Clinical Diagnostics, Rochester, NY) 
Vitros 
HIV/1-HIV/2 antigen/antibody 
combination immunoassay 
“4th generation”a 
Architect HIV Ag/Ab Combo 
(Abbott Laboratories, Abbott Park, IL) 
Architect Ag/Ab 
GS HIV Combo Ag/Ab EIA 
(Bio-Rad Laboratories, Redmond, WA) 
GS Ag/Ab 
HIV-1 Western blot GS HIV-1 Western Blot 
(Bio-Rad Laboratories, Redmond, WA) 
WB 
Cambridge Biotech HIV-1 Serum Western Blot 
(Maxim Biomedical, Inc. Rockville, MD) 
WB 
HIV-1/HIV-2 differentiation assay Multispot HIV-1/HIV-0 Rapid Test 
(Bio-Rad Laboratories, Redmond, WA) 
Multispot 
HIV-1 nucleic acid amplification testb APTIMA HIV-1 RNA Qualitative Assay 
(Hologic Gen-Probe Inc., San Diego, CA) 
APTIMA 
Procleix Ultrio 
(Novartis Diagnostics, Cambridge, MA) 
Procleix 
a The Determine HIV 1-2 Ag/Ab Combo rapid test, approved by the FDA in August 2013, was not included in the evidence synthesis because 
there were no studies evaluating its performance as part of the algorithm. 
b APTIMA, FDA-approved for HIV diagnosis, and Procleix Ultrio, FDA-licensed for screening blood donations, are two brand names for the 
same qualitative RNA assay.  
C. Quality of Evidence  
The quality of available studies comparing the performance of individual HIV tests or algorithms 
was inherently limited. No randomized controlled trials comparing individual assays or 
algorithms were conducted with specimens from populations with unknown infection status. 
Limitations affected many of the studies identified during the literature review and are identified 
for each study in the tables of evidence (Appendix 2, Section E).  
• Nearly all studies identified during the literature review were cross-sectional analyses 
that used previously tested specimens and compared test results with a reference standard 
in different studies and not directly with each other in the same study. Because the 
prevalence of acute HIV-1 infection and HIV-2 infection is extremely low in the United 
States, testing specimens from a population representative of persons screened for HIV 
infection in the United States would yield very few cases of these infections. Studies 
therefore used specimen collections enriched with specimens from known cases of acute 
HIV-1 infection or HIV-2 infection to allow performance evaluations using a smaller 
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number of specimens and a shorter time frame. These were the only study designs that 
could feasibly answer questions of accuracy, but such studies might be subject to 
selection bias. 
• Available studies evaluated tests and algorithms against different reference standards for 
a laboratory diagnosis of HIV-1 or HIV-2 infection. Some of the HIV-1 NAT or HIV-2 
assays that were used are not FDA-approved for HIV diagnosis. Differences in reference 
standards can reduce the comparability of results for index tests evaluated in different 
studies.  
• No studies conducted all assays on all specimens. Studies initiated testing with different 
immunoassays, and selected specimens for additional testing based on repeatedly reactive 
immunoassay results or conducted pooled HIV-1 NAT on immunoassay-negative 
specimens. Some studies conducted only HIV-1 Western blot or HIV-1 IFA; others also 
performed HIV-1 NAT. These procedures might result in selection bias and reduce the 
comparability of results for index tests. 
• Studies of previously tested specimen sets did not specify whether testing personnel were 
unaware of the results of the previous tests (“blinded”) before conducting the index test. 
This might have resulted in biased interpretation of test results, especially for assays that 
require subjective interpretation of results, such as the HIV-1 Western blot and HIV-
1/HIV-2 antibody differentiation assay.  
• Studies that present longitudinal data on natural history of HIV-1 infection such as 
seroconversion panels typically have small numbers of subjects because subjects must 
provide multiple blood specimens over a period of weeks or months. The small numbers 
may not be representative of all persons in populations at risk for HIV-infection.  
• The 4th generation antigen/antibody combination immunoassays were only recently 
FDA-approved for clinical use. This limited the number and size of studies that evaluated 
these tests, which resulted in wide confidence intervals for point estimates in some 
studies. 
Studies that systematically assessed sensitivity, specificity, and accuracy (key questions 1, 2, and 
3) are identified in the tables of evidence. No studies systematically assessed the minimum 
number of assays necessary to obtain an accurate laboratory diagnosis (key question 4) or 
compared the harms and benefits of the previous and recommended algorithms (key question 6). 
Three models examined cost and cost effectiveness (key question 5), but no observational studies 
directly compared costs of the previous and recommended algorithms. Available data related to 
key questions 4, 5, and 6 are included and cited in the summary of evidence.  
Twelve studies directly compared two or more different immunoassays on the same 
specimens.18,46,47,49,63,66,70,71,76,94,123,141 Four of these tested the same specimens from 
seroconversion panels at different times.46,47,49,66 Fourteen studies evaluated the performance of 
different immunoassays and algorithms with different specimen collections and compared results 
to a reference standard.18,29,47,71,72,76,88,107,142-147 Four studies of assay performance for acute HIV-
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1 infection used specimens that had been identified by pooled HIV-1 RNA screening programs 
and collected and stored consistent with requirements specified for the assay by the 
manufacturer.18,62,71,72 Two studies of previously tested specimens with negative or indeterminate 
Western blot results conducted retrospective testing with the HIV-1/HIV-2 differentiation assay 
and HIV-1 NAT, but had no information about whether specimens were stored and handled 
consistent with requirements for the HIV-1 NAT assays.148,149 
CDC writing group members did not conduct pooled data analyses because the studies were 
conducted with different assays of the same or different classes (that is, three 3rd generation and 
two 4th generation immunoassays) using specimen collections from different populations with 
different pre-test probabilities of infection, or enriched with pedigreed specimens with known 
laboratory diagnosis of HIV-1 or HIV-2 infection. The number of significant digits reported for 
values in the evidence summary and tables are those as published in the original studies. The 
writing group did not conduct recalculations or rounding. 
Inferring that an accurate test result improves outcomes important to patients requires availability 
of effective treatment, improved well-being through prognostic information, and, by excluding 
an ominous diagnosis, reduction of anxiety.138 The workgroup relied on other systematic reviews 
and recommendations for documentation of benefits and harms associated with screening and 
diagnostic testing for HIV in different populations, effectiveness of treatment for persons with 
HIV infection, and interventions for HIV-negative persons.23,150-156  
D. Summary of Evidence Supporting the Recommendations 
1. Sensitivity of individual assays 
a. What is the sensitivity of individual assays for established HIV-1 and HIV-2 infections? 
1.a.1. The sensitivity of immunoassays for established HIV-1 and HIV-2 infections is 
very high and comparable for all FDA-approved 3rd generation and 4th 
generation immunoassays. Sensitivities of the 3 FDA-approved 3rd generation 
assays for established HIV-1 infection ranged from 99.80% to 100% (4 studies 
and 3 product inserts),46,47,49,94,157-159 and of the 2 FDA-approved 4th generation 
assays, 99.76% to 100% (4 studies and 2 product inserts).46,47,72,143,160,161 Few 
independent studies have examined sensitivity for HIV-2. One study that 
evaluated a 3rd generation HIV-1/HIV-2 immunoassay and one with a 4th 
generation HIV-1/HIV-2 combination immunoassay found 100% sensitivity for 
HIV-2.49,144 Data from manufacturers indicate FDA-approved 3rd and 4th 
generation HIV-1/HIV-2 immunoassays are 100% sensitive for HIV-2.143,157-161  
1.a.2. Only NATs for HIV-1 RNA, which do not detect HIV-2,49,162 are FDA-approved. 
Sensitivity of HIV-1 NAT for established HIV-1 infection is lower than that of 
immunoassays. In 2 cross-sectional and 2 prospective studies, HIV-1 RNA NAT 
produced negative results in 2% to 4% of specimens that were reactive on 3rd 
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generation immunoassays and positive on HIV-1 Western blot.18,49,142,145 Some 
specimens with undetectable RNA might have come from persons taking ART, 
but one study documented NAT-negative specimens from antibody-positive 
persons who were not receiving ART.18 Some NAT-negative specimens might 
have come from persons who suppress HIV replication without ART (so-called 
elite controllers).163,164 However, this phenomenon is estimated to occur in only 1 
of 300 persons with HIV infection.165  
1.a.3. Only one assay is FDA-approved for differentiating HIV-1 from HIV-2 
antibodies. Criteria for a positive interpretation as revised in March 2013 require 
the presence of both HIV-1 indicators (synthetic gp41 peptide and recombinant 
gp41 protein) when the assay is used as a supplemental test; presence of only one 
indicator is interpreted as an indeterminate result.166 Sensitivity of the 
differentiation assay for established HIV-1 infection in 9 studies ranged from 
98.5% to 100%, but not all studies reported whether their diagnostic criteria 
required one or both of the HIV-1 indicators.29,47,63,76,88,107,118,146,147 In 2 studies 
that required both indicators, 11 (85%) of 13 specimens and 8 (89)% of 9 
specimens with only one HIV-1 indicator had either a positive HIV-1 Western 
blot result or detectable HIV-1 RNA.76,118  
Four studies reported the results of parallel testing of specimens with the HIV-1 
Western blot and the HIV-1/HIV-2 antibody differentiation assay. One 
prospective study of 993 specimens repeatedly reactive by 3rd or 4th generation 
immunoassays identified 882 specimens reactive for HIV-1 only on the antibody 
differentiation assay.107 HIV-1 Western blot was positive in 871 and 
indeterminate in 11 of these specimens. Six of the 11 patients with indeterminate 
results were eventually traced and found to have serologically confirmed HIV-1 
infection. In this same study, 3 specimens were reactive for HIV-2 and 5 
specimens were reactive for both HIV-1 and HIV-2 on the antibody 
differentiation assay (1 with strong reactivity for both HIV-1 and HIV-2, 3 with 
strong HIV-1 and weak HIV-2 indicators, and 1 with weak reactivity for both 
HIV-1 and HIV-2).107 The 3 specimens reactive for HIV-2 only and the specimen 
with strong dual reactivity were positive by HIV-2 immunoblot and negative by 
HIV-1 NAT; the dually reactive specimen also had detectable HIV-2 RNA.107 All 
4 HIV-2 specimens showed 3 or 4 bands on the HIV-1 Western blot, sufficient to 
classify 3 as HIV-1 positive and 1 as indeterminate. The 3 specimens with strong 
HIV-1 reactivity and weak HIV-2 reactivity were reactive for all bands on the 
HIV-1 Western blot and negative on the HIV-2 immunoblot. The specimen with 
weak reactivity for both HIV-1 and HIV-2 was reactive only to the gp160 band 
on HIV-1 Western blot and negative by HIV-2 immunoblot; volume was 
insufficient for HIV-1 NAT.107  
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In a study of 8,760 specimens repeatedly reactive by 3rd generation 
immunoassay, the HIV-1/HIV-2 antibody differentiation assay classified 26 
(0.3%) of 8,678 specimens with positive HIV-1 Western blot results and 12 
(19%) of 63 specimens with indeterminate HIV-1 Western blot results as HIV-2, 
but no other HIV-2 tests were performed to validate these results.88 In a second 
study, the HIV-1/HIV-2 differentiation assay was positive for HIV-1 in 491 and 
for HIV-2 infection in 2 (0.4%) of 493 specimens that had positive HIV-1 
Western blot results; these 2 were also positive by HIV-2 Western blot.47 One 
retrospective study of 34 specimens and the product insert description of 207 
specimens demonstrated 100% sensitivity of the HIV-1/HIV-2 differentiation 
assay for HIV-2.49,166  
b. What is the sensitivity of individual assays for acute HIV-1 infection?  
1.b.1. Third generation HIV-1/HIV-2 assays, fourth generation HIV-1/HIV-2 
antigen/antibody combination assays, and HIV-1 RNA assays each confer 
incremental improvements in sensitivity for acute HIV-1 infection. Retrospective 
testing of specimens from high-risk persons demonstrated that 3rd generation 
immunoassays were reactive in 20% to 37% and 4th generation assays were 
reactive in 62% to 83% of specimens that were negative by HIV-1 Western blot 
but reactive by HIV-1 NAT.69,70,72,73 In a study of 228 specimens from 26 
commercial HIV-1 seroconversion panels, HIV-1 Western blot was positive in 56 
specimens (25%); 3 different 3rd generation assays were reactive in 102 (44.7%), 
108 (47.4%), and 111 (48.6%) specimens, respectively, and 2 different 4th 
generation assays were reactive in 131 (57.5%) and 135 (59.2%) specimens.46,47 
In 3 retrospective studies of 42 specimens with detectable HIV-1 RNA but 
nonreactive 3rd generation antibody immunoassays, 62% to 77% were reactive 
by 4th generation HIV-1/HIV-2 antigen/antibody combination 
immunoassays.18,73,167 In a study involving retrospective testing of 74 specimens 
reactive by HIV-1 NAT after negative 1st or 2nd generation immunoassays, 
Western blot was positive in 12.5%, a 3rd generation immunoassay was reactive 
in 42.2%, and a 4th generation immunoassay was reactive in 89.1%.71 In one 
study of 99,111 specimens screened with immunoassays, HIV-1 Western blot, 
and pooled NAT, 1,186 specimens were positive by either HIV-1 Western blot or 
HIV-1 NAT.18 Pooled HIV-1 NAT increased the yield of new HIV diagnoses by 
2.2% in specimens with a nonreactive 3rd generation immunoassay and by 0.7% 
in specimens with a nonreactive 4th generation immunoassay.18  
1.b.2. The HIV-1/HIV-2 antibody differentiation assay detects HIV-1 infection earlier 
than the HIV-1 Western blot. In one prospective study, Multispot was reactive 
for HIV-1 in 11 specimens that were indeterminate by HIV-1 Western blot; 6 of 
the 11 patients were eventually traced and serologically confirmed to have HIV-1 
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infection.107 Two studies of 183 specimens from 15 seroconverters demonstrated 
the HIV-1/HIV-2 differentiation assay became reactive 7 days before the HIV-1 
Western blot.46,49 Among 8,760 specimens repeatedly reactive by 3rd generation 
immunoassay, the HIV-1/HIV-2 differentiation assay was reactive for HIV-1 in 3 
(15.8%) of 19 specimens that were negative by HIV-1 Western blot and in 11 
(17.5%) of 63 specimens indeterminate by HIV-1 Western blot.88 Five studies 
documented reactive HIV-1/HIV-2 antibody differentiation assay results in 
specimens repeatedly reactive by 3rd or 4th generation IA, reactive by HIV-1 
NAT, but negative or indeterminate by HIV-1 Western blot.47,76,107,148,149 
2. What is the specificity of individual assays in specimens from uninfected persons? 
Most studies compared immunoassays with specimens defined as negative for HIV by 
negative immunoassay or HIV-1 Western blot results. Thus, specificity estimates for 
immunoassays from such studies might be artificially lowered by specimens from persons 
with acute or recent HIV infection that were misclassified as negative by the Western 
blot.63,70 
a. Specificities of the 3 FDA-approved 3rd generation assays ranged from 99.13% to 100% 
(6 studies, 3 product inserts).46,47,49,94,141,157-159,168  
b. Specificities of the 2 FDA-approved 4th generation assays ranged from 99.50% to 100% 
(6 studies, 2 product inserts).46,47,72,141,143,160,161,168  
c. Specificity of the HIV-1/HIV/2 differentiation assay ranged from 99.03% to 99.93% (3 
studies, product insert).46,63,166,169 
d. No recent studies examined Western blot results in specimens without previous 
repeatedly reactive immunoassay results. A 1990 study demonstrated indeterminate 
Western blot results in 32% of healthy adults.170  
e. Specificity of HIV-1 NAT for HIV-1 infection was 99.6% in one retrospective study of 
513 reference-negative specimens49 and 99.9% in 2 studies of pooled NAT screening of 
HIV-1 antibody-negative specimens.16,18 The 2 studies of pooled NAT screening reported 
follow-up test results on persons with NAT-reactive specimens. In one, 1 of 5 persons 
with NAT-reactive results from 8,505 antibody-negative specimens did not seroconvert;16 
in the second, 3 of 15 persons with NAT-reactive results from 54,000 specimens 
screened did not seroconvert.18  
3. Accuracy of algorithms based on combinations of assays 
a. What is the accuracy of algorithms based on combinations of assays in specimens from 
persons with established HIV-1 infection? 
Six studies indicate that the accuracy of the recommended algorithm is equivalent to or 
better than that of the previous algorithm for correctly classifying established HIV-1 
infections; it also produces fewer indeterminate results. The New York State laboratory’s 
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routine testing algorithm allowed direct comparison of the recommended and previous 
algorithms on 38,257 specimens that were tested prospectively with a 3rd generation 
immunoassay followed by both Western blot and HIV-1/HIV-2 antibody differentiation 
immunoassay on repeatedly reactive specimens and HIV-1 RNA NAT on HIV-2-
negative, Western blot-negative, or indeterminate specimens. The recommended 
algorithm correctly classified 1,578 (100%) specimens as HIV-1 positive; the previous 
algorithm classified 1,546 (98%) as HIV-1 positive, 4 as negative, and 28 as 
inconclusive.76 In 4 retrospective studies of more than 3,200 HIV-1 Western blot-positive 
specimens, correct results when the recommended algorithm was initiated with 3rd 
generation immunoassays ranged from 99.8% to 100%.47,70,94,123 Three similar studies 
that initiated retrospective testing with 4th generation immunoassays on 4,200 HIV-1 
Western blot-positive specimens did not demonstrate a statistically significant difference 
between the results of the recommended and the previous algorithms.46,47,123  
b. What is the accuracy of algorithms based on combinations of assays in specimens from 
persons with acute HIV-1 infection? 
In two studies using 230 specimens from the same seroconversion panels, the new 
algorithm with two 3rd generation assays as the initial test correctly identified acute HIV-
1 infections in 14 (6.1%) and 12 (5.2%) specimens, respectively, that were negative with 
the previous algorithm.46,47 With the two 4th generation assays as the initial test, the 
recommended algorithm identified acute HIV-1 infections in 36 (15.7%) and 41 (17.8%) 
specimens, respectively, that were negative with the previous algorithm.46,47 One ongoing 
prospective study identified 654 specimens that were repeatedly-reactive by 4th 
generation antigen/antibody immunoassay.10 HIV-1/HIV-2 antibody differentiation assay 
results were reactive in 555 (84.9%) specimens and negative or indeterminate in 99 
(15.1%). HIV-1 RNA NAT was reactive in 55 (55.6%) of these 99: 47 (52.2%) of 90 
specimens with negative and 8 (88.9%) of 9 specimens with indeterminate HIV-1/HIV-2 
antibody differentiation immunoassay results.118 One study of 37 patients with repeatedly 
reactive 4th generation antigen/antibody combination immunoassay results identified 
detectable HIV-1 RNA in 11 (29.7%) specimens with nonreactive HIV-1/HIV-2 antibody 
differentiation assay results.10 Two studies retrospectively tested specimens that were 
Western blot-negative or indeterminate after repeatedly reactive 3rd generation 
immunoassays with the HIV-1/HIV-2 differentiation immunoassay and HIV-1 NAT. In 
one, application of these two supplemental tests identified HIV-1 infections in 184 
(5.6%) of 3,273 specimens; 96 (2.9%) were acute HIV-1 infections.148 In the second 
study, among 570 specimens obtained from public health laboratories, application of the 
two supplemental tests identified HIV-1 infection in 55 (9.6%); 19 (3.3%) were acute 
HIV-1 infections.149 In a prospective analysis of 51,000 specimens during the first 5 
months using the recommended testing algorithm in the Florida Bureau of Public Health 
Laboratories, the recommended algorithm detected 922 HIV-1 infections, of which 4 
(0.4%) were acute.123 In prospective analysis after implementation of the recommended 
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algorithm with 7,984 specimens from Massachusetts, 8 (3.1%) of 258 HIV-1 infections 
were acute.167 
c. What is the accuracy of algorithms based on combinations of assays in specimens from 
persons with established HIV-2 infection? 
This question could not be answered directly because there is no FDA-approved NAT 
for HIV-2 and different diagnostic criteria were used in studies of HIV-2 infections. 
According to the previous recommendations, specimens with a positive HIV-1 Western 
blot would not undergo specific testing for HIV-2;2 most studies evaluating algorithms 
involved specimens with evidence of HIV-2 infection that had been misclassified as 
HIV-1 infection. In a prospective study, parallel testing with both the differentiation 
assay and HIV-1 Western blot classified 26 (0.29%) of 8,678 HIV-1 Western blot-
positive specimens as HIV-2.88 In a retrospective study, the recommended algorithm 
reclassified 2 (0.4%) of 493 specimens with positive HIV-1 Western blot results as 
HIV-2.47  
d. What is the accuracy of algorithms based on combinations of assays in specimens from 
persons not infected with HIV?  
The recommended algorithm accurately classifies more persons who are not infected 
with HIV than the previous algorithm by reducing the number of specimens with 
indeterminate test results. In the New York State analysis that directly compared the 
recommended and previous algorithms after an initial 3rd generation immunoassay on 
the same specimens, the recommended algorithm classified 36,661 (99.98%) specimens 
as negative compared with 36,649 (99.95%) by the previous algorithm.76 In this study, 48 
(2.9%) specimens had indeterminate HIV-1 Western blot results with the previous 
algorithm. Applying test results from the recommended algorithm, only 9 (0.5%) of these 
48 specimens would have been classified as inconclusive by the recommended algorithm, 
because the specimens submitted were unsuitable for NAT testing.76 A study of 10,014 
specimens from life insurance applicants with low HIV prevalence identified 13 (0.1%) 
specimens repeatedly reactive on at least one 3rd or 4th generation immunoassay.47 Two 
were classified as HIV-1 positive by both the previous and recommended algorithms. 
One specimen repeatedly reactive only by 3rd generation and 8 repeatedly reactive only 
by 4th generation were negative by both algorithms. One specimen repeatedly reactive 
only by 3rd generation and one specimen repeatedly reactive only by 4th generation 
immunoassay were indeterminate by the previous algorithm and negative by the 
recommended algorithm.47 
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4. What algorithm(s) required the fewest assays to maximize accuracy and minimize 
indeterminate or inconclusive test results? 
a. Required supplemental assays 
The recommended algorithm requires a lower number of assays than the previous 
algorithms to obtain accurate test results for HIV-1 and HIV-2 for most specimens. Both 
the previous and recommended algorithms include 1 initial assay and 1 or 2 supplemental 
assays. The recommended algorithm requires one supplemental assay if HIV-1 or HIV-2 
antibodies are present; it eliminates the need to use a second supplemental assay to test 
for HIV-2 antibodies. If results of the first supplemental assay are negative or 
indeterminate, it requires a second supplemental assay, HIV-1 NAT, to test for acute 
HIV-1 infection and eliminate indeterminate results. Three studies show that only 0.1% 
to 0.2% of all specimens required NAT testing to identify acute HIV-1 infections or 
false-positive immunoassay results.47,123,167 The previous algorithm requires 1 
supplemental assay to test for HIV-1 antibodies. If the result of this first supplemental 
assay is negative or indeterminate, it requires a second supplemental assay to test for 
HIV-2 antibodies. The previous algorithm cannot identify acute HIV-1 infection, and 
indeterminate specimens that are negative for HIV-2 antibodies require testing of a 
follow-up specimen for HIV-1. Three studies indicate the previous algorithm produces 
indeterminate results in from 1.9% to 4.5% of specimens with repeatedly reactive 3rd or 
4th generation immunoassays.29,76,118 With both algorithms, HIV-1 antibody-positive 
specimens are resolved with 2 assays; specimens that are false-positive on the initial 
assay require 3 tests. 
b. HIV-1 NAT screening of specimens negative for HIV antibodies  
HIV-1 NAT screening after a negative 3rd or 4th generation immunoassay can identify 
more acute HIV infections than 4th generation immunoassays, but an antibody 
immunoassay must also be used on all specimens with a negative HIV-1 NAT because 
HIV-1 NAT is negative in 2% to 4% of specimens with established HIV-1 infection and 
in all specimens with HIV-2 infection.18,49,145 If used as the second test in the algorithm, 
HIV-1 NAT would fail to distinguish acute from established infections, and tests for 
HIV-1 and HIV-2 antibody would still be required for specimens with negative HIV-1 
NAT results. Using HIV-1 NAT as the first or second test in the algorithm would 
increase the number of tests necessary for accurate diagnosis, increase turnaround time 
for final results, and increase costs.142,171  
c. HIV-1/HIV-2 Differentiation Assay 
Using an HIV-1/HIV-2 antibody differentiation assay as the supplemental test in the 
recommended algorithm can reduce the number of assays because it can identify and 
differentiate HIV-1 and HIV-2 antibodies in a single step. The differentiation assay also 
incorporates two different antigenic determinants for HIV-1 (synthetic gp41 peptide and 
recombinant gp41 protein), so a laboratory diagnosis of HIV-1 is based on 3 concordant 
Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations  http://stacks.cdc.gov/view/cdc/23447 42 
reactive test results (the initial immunoassay and both HIV-1 determinants in the 
differentiation assay).76,88,149,166 CLIA classifies the FDA-approved differentiation assay 
as “moderate complexity”166 so it can be performed by laboratories that are not certified 
to conduct high complexity assays, such as the Western blot, increasing the number of 
laboratories that can perform both the initial and supplemental assays in the 
recommended algorithm. 
d. Testing specimens submitted after reactive single-use rapid HIV test results 
CDC’s 2004 recommendation to confirm all reactive rapid tests by HIV-1 Western blot 
or HIV-1 IFA regardless of results of initial laboratory immunoassays was based on 
observations of false-negative results from the laboratory immunoassay then in 
predominant use,74 which was discontinued by the manufacturer in 2007. Three studies 
that conducted all HIV tests approved by the FDA as of December 2013 on the same 166 
plasma specimens from 16 seroconverters indicated that, for tests FDA-approved as of 
May 2014, 4th generation laboratory-based combination antigen/antibody immunoassays 
become reactive earlier during early infection than any of the single-use rapid HIV tests, 
including the 4th generation antigen/antibody combination rapid HIV test.46,49,63 One 
prospective evaluation of 428 specimens submitted after reactive rapid test results 
demonstrated all were correctly classified by the recommended algorithm.123 A 
nonreactive antigen/antibody combination immunoassay result after a reactive rapid HIV 
test result indicates a false-positive rapid HIV test result and averts the need to conduct 
additional supplemental testing.  
5. Do the costs and cost-effectiveness of the recommended algorithm for the diagnosis of HIV 
infection differ from the costs and cost-effectiveness of the previous algorithm? 
Comparing laboratory costs for testing algorithms is difficult because assay costs vary over 
time, in different laboratories, and with different testing volumes. Testing costs also depend 
on the prevalence of established and acute HIV infections in tested specimens (and thus the 
number of supplemental tests required).99 Investigators collected cost information from 17 
clinical and public health laboratories and used the median cost in a model to compare the 
cost of previous algorithm and the recommended algorithm. (The model did not include costs 
or effectiveness for the laboratory diagnosis of HIV-2 infection.) The recommended algorithm 
identified more specimens with HIV-1 infection. It was less costly than the previous algorithm 
for specimens positive for HIV antibody, but more costly for the subset of specimens that 
required HIV-1 NAT to evaluate acute infection or false-positive initial immunoassay 
results.99 Estimates of both the number of HIV infections detected and overall laboratory 
testing costs were higher with the recommended algorithm than with the previous algorithm.99 
In specimens with 1% prevalence of established HIV-1 infection and 0.1% prevalence of 
acute HIV-1 infection (characteristic of specimens from high-risk populations), the model 
estimated that, compared with the previous algorithm, the incremental cost per additional 
HIV-1 infection detected ranged from $5,027 to $14,400. In contrast, for specimens in which 
 Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations  Published June 27, 2014 43 
the prevalence of established and acute HIV-1 infections is very low (0.01% and 0.001%, 
respectively), incremental cost-effectiveness of the recommended algorithm exceeds $100,000 
per additional infection detected compared with the previous algorithm. A different cost-
effectiveness model that included as an outcome the costs of cases averted by early detection 
of HIV infection concluded that HIV testing remained cost saving until costs per new HIV 
diagnosis exceeded $22,903.172 
Two other U.S. models evaluated the cost-effectiveness of alternative algorithms in which 
pooled HIV-1 NAT would directly follow an initial nonreactive 3rd generation immunoassay. 
Both used cost per quality adjusted life year as outcomes. One found that the incremental 
cost-effectiveness of pooled HIV-1 NAT exceeded $100,000 per quality-adjusted life year 
unless prevalence of acute HIV infection in tested specimens exceeded 0.4%.173 The second 
model found that screening with a 4th generation immunoassay was more economical than 
pooled NAT screening after a negative 3rd generation immunoassay.171 In both studies, the 
cost-effectiveness of each strategy varied considerably with the prevalence of undiagnosed 
HIV infection and the frequency of re-testing (which influences the proportion of specimens 
with acute HIV-1 infection). 
6. Do benefits and harms for patients associated with the proposed diagnostic algorithm differ 
from benefits and harms associated with the previous diagnostic algorithm? 
The recommended algorithm is associated with additional benefits and fewer harms for 
patients than the previous algorithm. By reducing the number of false-negative and 
indeterminate results and misclassified HIV-2 infections, the recommended algorithm is more 
accurate. The previous algorithm produces indeterminate results in from 2% to 4.5% of 
persons with repeatedly reactive 3rd or 4th generation immunoassays, which require testing of 
additional follow-up specimens.29,76,118 By reducing indeterminate test results, the 
recommended algorithm reduces delays in HIV diagnosis, anxiety for tested persons, and the 
inconvenience and cost of collecting additional specimens for more testing.174,175 The 
recommended algorithm only rarely requires additional specimens; for example, when an 
HIV-1 NAT is required and the original specimen is unsuitable. This may be inconvenient or 
provoke anxiety in tested persons. However, one testing program that initiated a new shipping 
service to speed delivery of specimens found that the laboratory considered only 1.6% of 
specimens submitted unsuitable for testing.167  
The recommended algorithm can also reduce turnaround time for test results compared with 
the previous algorithm. One public health laboratory using the recommended algorithm was 
able to report 96% of antibody-positive test results in 2 workdays or less, compared with 22% 
when specimens were tested with the previous algorithm.123 Another testing program that 
replaced the previous algorithm with the recommended algorithm was able to shorten the 
interval between specimen collection and routine notification of test results by 1 week.167 
Turnaround time for test results is longer for specimens that required HIV-1 NAT testing as 
part of the algorithm, but no studies documented the time necessary to obtain the NAT results. 
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E. Tables of Evidence  
The following tables identify the specific studies and their limitations and strengths for 
sensitivity, specificity, and accuracy (key questions 1a, 1b, 2, 3a, 3b, 3c, and 3d). The tables of 
evidence denote the limitations and strengths that influenced the quality of evidence provided by 
each study using the following key: 
Limitations: 
A. Possible selection bias: Selection of specimens was not consecutive or random. 
Specimen collections that were comprised of previously tested specimens known to 
have a laboratory diagnosis of established HIV-1 infection, acute HIV-1 infection, or 
HIV-2 infection do not reflect pre-test probability of these infections in different 
populations in the United States that undergo HIV testing.  
B. Incomplete information or lack of peer review: Evidence quality reduced when 
format of information from manufacturer’s product inserts did not provide detailed 
information needed for interpretation such as source of specimens or the identity of 
all tests used as reference standards, or summaries of unpublished data are based on 
studies that were not subject to independent peer review (other than by FDA experts). 
C. Indirect comparisons of test performance: Evidence quality is reduced when a 
study evaluates only one index test against a reference standard, and not directly 
against other index tests on the same specimens in the same study. Indirect 
comparisons can be prone to selection bias. 
D. Comparison with different, composite, or unspecified reference standards: 
Evidence quality is reduced if different reference standards were employed (for 
example, in the absence of a published standard for HIV-2 infection), if the same 
standard was not used for all specimens (for example, HIV-1 NAT applied to 
specimens with negative or indeterminate but not positive HIV-1 Western blot 
results), or if the study did not define the reference standard used for all specimens.  
E. Uncertainty about specimen integrity: Evidence quality is reduced if uncertainty 
exists about whether handling or storage of previously tested specimens was 
inconsistent with the requirements for reliable test results from subsequent testing by 
index or reference tests. 
F. Small size of specimen collections: Testing of <100 specimens yields very wide 
confidence intervals around point estimates and might be more affected by selection 
bias.  
Strengths: 
AA. Specimens prospectively collected for diagnostic testing: Studies that conducted 
testing on specimen sets obtained as part of routine diagnostic testing are more 
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representative of the populations that will be tested with the recommended algorithm 
and less likely to be affected by selection bias. 
BB.  All studies evaluated, except manufacturers’ package inserts, were subject to peer 
review. Therefore, peer review was not denoted as a strength for any study and BB is 
not an entry in the Strengths column of the evidence tables.  
CC.  Direct comparisons of different tests on the same specimen sets: Direct 
comparisons improve the validity of performance comparisons of index tests. 
DD.  Comparison with the same reference standard: Evidence quality is improved if all 
specimens in the study were compared to the same reference standard, and results 
were compared to other studies that applied the same reference standard. 
EE.  Although specimen handling, when uncertain, is noted as a weakness, appropriate 
handling and storage of specimens consistent with obtaining reliable test results were 
not specifically denoted as strengths. Therefore, EE is not an entry in the Strengths 
column of the evidence tables.  
FF.  Large sample size: Testing of >1,000 specimens yields narrow confidence intervals 
around point estimates. 
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Evidence Table 1.a. Sensitivity of assays for established HIV-1 and HIV-2 infection, by corresponding section in Summary of Evidence  
Publication Test evaluated Specimen characteristics 
Number of 
specimens Reference standard 
Sensitivity 
n reactive/n tested (%) 
95% confidence 
interval Limitations Strengths 
1.a.1. Third generation immunoassay sensitivity for established HIV-1 
Owen; 200849  GS Plus O Previously tested, WB-positive 
specimens from U.S. and non-
U.S. blood donors 
621 HIV-1 WB 620/621 (99.8) Not reported A CC,DD 
Masciotra; 
201146 
GS Plus O  Previously tested, WB-positive 
specimens from high-risk U.S. 
populations 
416 HIV-1 WB 416/416 (100) 99.09–100 A CC,DD 
Nasrullah; 
201347 
GS Plus O Previously tested, WB-positive 
specimens from a U.S. 
commercial laboratory 
493 HIV-1 WB 493/493 (100) Not reported A CC,DD 
Wesolowski; 
201194 
a) GS Plus O 
b) VITROS 
c) ADVIA  
Previously tested, WB-positive 
specimens from high-risk U.S. 
populations 
a) n=2,202 
b) n=1,109 
c) n=1,108 
HIV-1 WB a) 2,202/2,202 (100) 
b) 1,109/1,109 (100) 
c) 1,108/1,108 (100) 
a) 99.83–100 
b) 99.67–100 
c) 99.67–100 
A CC,DD,FF 
Product insert157 GS Plus O Prospectively collected 
specimens from a) U.S. and 
b) non-U.S. persons known to 
be positive for HIV-1 antibody, 
c) persons with AIDS, and 
d) 1,011 high-risk persons from 
United States and Canada 
a) 490 
b) 199 
c) 313 
d) 19 
HIV-1 WB a) 490/490 (100) 
b) 199/199 (100) 
c) 313/313 (100) 
d) 19/19 (100) 
a) Not reported 
b) Not reported 
c) 99.84–100 
d) Not reported 
a) A,B,C 
b) A,B,C 
c) A,B,C 
d) B,C,F 
a) DD 
b) DD 
c) DD 
d) AA,DD 
Product insert158 VITROS Prospectively collected 
specimens from a) U.S. adults 
and children known to be 
infected with HIV-1 and b) 2,424 
U.S. high-risk adults 
a) 1,161 
b) 59 
a) Medical record 
evidence of HIV-1 
antibody 
b) HIV-1 WB 
a) 1,161/1,161 (100) 
b) 59/59 (100) 
a) 99.68–100 
b) Not reported 
a) A,B,C,D 
b) B,C,F 
a) FF 
b) AA,DD 
Product insert159 ADVIA  Prospectively collected 
specimens from a) U.S. persons 
known to be infected with HIV-1 
and b) 554 U.S. persons from 
high-risk populations  
a) 1,059 
b) 14 
HIV-1 WB a) 1,059/1,059 (100) 
b) 14/14 (100) 
a) 99.72–100 
b) Not reported 
a) A,B,C 
b) B,C,F 
a) DD,FF 
b) AA,DD  
1.a.1. Fourth generation immunoassay sensitivity for established HIV-1 
Masciotra; 
201146 
Architect Ag/Ab Previously tested, WB-positive 
specimens from high-risk U.S. 
populations 
416 HIV-1 WB 415/416 (99.76) 99.08–100 A CC,DD 
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Publication Test evaluated Specimen characteristics 
Number of 
specimens Reference standard 
Sensitivity 
n reactive/n tested (%) 
95% confidence 
interval Limitations Strengths 
Chavez; 201172 Architect Ag/Ab Previously tested WB-positive 
and WB-negative specimens 
from high-risk U.S. populations 
3,386 HIV-1 WB or other 
antibody test and HIV-
1 NAT 
3,384/3,386 (99.94) 99.79–99.99 A,D FF 
Nasrullah; 
201347 
GS Ag/Ab Previously tested WB-positive 
specimens from a U.S. 
commercial laboratory 
493 HIV-1 WB 493/493 (100) Not reported A CC,DD 
Bentsen; 2011143 GS Ag/Ab Previously tested HIV-1 
antibody-positive specimens 
from a) U.S. adults, b) non-U.S. 
adults, c) persons with AIDS, 
d) children, and f) 1,000 high-
risk STD clinic patients 
a) 1000 
b) 200 
c) 100 
d) 40 
e) Total 
f) 40 
a,b,c,d,e) FDA-
licensed HIV-1/HIV-2 
enzyme IA 
f) HIV-1 WB 
a) 1000/1000 (100) 
b) 200/200 (100) 
c) 100/100 (100) 
d) 40/40 (100) 
e) 1,340/1,340 (100) 
f) 40/40 (100) 
a) Not reported  
b) Not reported  
c) Not reported  
d) Not reported  
e) 99.71–100 
f) Not reported 
a) A,C,D 
b) A,C,D 
c) A,C,D 
d) A,C,D 
e) A,C,D 
f) F 
a) FF 
b) 
c) 
d) 
e) FF 
f) AA,DD 
Product insert160 Architect Ag/Ab Prospectively collected 
specimens from a) HIV-infected 
and b) 693 high-risk U.S. adults  
a) 1,003 
b) 65 
HIV-1 WB a) 1,003/1,003 (100) 
b) 65/65 (100) 
a) 99.63–100 
b) Not reported 
a) A,B,C 
b) B,C,F 
a) DD,FF 
b) AA,DD 
Product insert161 GS Ag/Ab Previously tested known HIV-1 
antibody-positive specimens 
from U.S. and non-U.S. 
populations 
1,300 FDA-licensed HIV-
1/HIV-2 enzyme IA 
1,300/1,300 (100) 99.70–100 A,B,C,D FF 
1.a.1. Immunoassay sensitivity for HIV-2 
Owen; 200849 GS Plus O Previously tested HIV-2–positive 
specimens obtained 
commercially and from a non-
U.S. study 
34 HIV-2 NAT or 
immunoblot 
34/34 (100) Not reported A,D,F CC 
Malm; 2009144 Architect Ag/Ab Previously tested HIV-2–positive 
specimens obtained from non-
U.S. sources 
52 Not specified 52/52 (100) Not reported A,C,D,F  
Product insert157 GS Plus O Previously tested specimens 
from known HIV-2–positive 
persons, source not specified  
302 HIV-2 IA and HIV-2 
WB  
302/302 (100) 99.83–100 A,B,C  
Product insert158 VITROS Previously tested specimens 
from HIV-2 antibody-positive 
persons from Ivory Coast 
208 Not specified 208/208 (100) 98.24–100 A,B,C,D  
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Publication Test evaluated Specimen characteristics 
Number of 
specimens Reference standard 
Sensitivity 
n reactive/n tested (%) 
95% confidence 
interval Limitations Strengths 
Product insert159 ADVIA  Previously tested HIV-2 
antibody-positive specimens 
from commercial vendors in 
Africa 
197 HIV-2 immunoblot  197/197 (100) 98.49–100 A,B,C  
Bentsen; 2011143 GS Ag/Ab Previously tested HIV-2 
antibody-positive specimens 
from United States and Africa 
200 HIV-2 reactive on HIV-
1/HIV-2 differentiation 
IA 
200/200 (100) 98.11–100 A,B  
Product insert160 Architect Ag/Ab Previously tested HIV-2 
antibody-positive specimens 
from Cote d’Ivoire  
201 HIV-2 WB 201/201 (100) 98.18–100 A,B,C  
Product insert161 GS Ag/Ab Known HIV-2 antibody-positive 
specimens from U.S. and non-
U.S. sources 
200 Not specified 200/200 (100) 98.11–100 A,B,C,D  
1.a.2. Sensitivity of HIV-1 nucleic acid test for established HIV-1 
Patel; 201018 APTIMA Prospectively collected 
specimens from high-risk 
persons in U.S. HIV testing sites 
1,136 HIV-1 WB 1,094/1,136 (96.3) 
[28/42 specimens with negative 
APTIMA results from persons on 
ART] 
Not reported C AA,DD,FF 
Owen; 200849 Procleix Previously tested HIV-1 WB-
positive specimens from U.S. 
and non-U.S. blood donors 
621 HIV-1 WB 605/621 (97.4) Not reported A DD 
Ethridge; 2011142 APTIMA Previously tested HIV-1 WB-
positive serum and plasma 
specimens from U.S. HIV clinics 
325 HIV-1 WB Serum 316/325 (97.23) 
Plasma 317/325 (97.54) 
94.81–98.73 
95.21–98.93 
A,C DD 
Ren; 2008145 APTIMA Prospectively collected 
specimens from 1,361 persons 
in San Francisco HIV testing 
sites 
25 HIV-1 IFA 24/25 (96.0) Not reported D,F AA 
1.a.3. HIV-1/HIV-2 Ab differentiation assay sensitivity for established HIV-1  
Nasrullah; 
201129 
Multispot Retrospective analysis of test 
results from prospectively 
collected and tested specimens 
from New York State testing 
sites 
1,790 HIV-1 WB 1,787/1,790 (99.83) 
[1 specimen HIV-2 positive] 
Not reported  AA,DD,FF 
Pandori; 2013118 Multispot Prospectively collected and 
tested specimens from 3 U.S. 
study sites 
405 HIV-1 WB 398/405 (98.3) 
[5 specimens with Multispot 
indeterminate results]  
Not reported  AA,DD 
 Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations  Published June 27, 2014 49 
Publication Test evaluated Specimen characteristics 
Number of 
specimens Reference standard 
Sensitivity 
n reactive/n tested (%) 
95% confidence 
interval Limitations Strengths 
Delaney; 201163 Multispot Prospectively collected 
specimens from a high-risk U.S. 
population  
103 HIV-1 WB 103/103 (100) (97.13–100.0)  AA,CC 
Nasrullah; 
201347 
Multispot Previously tested WB-positive 
tested specimens from 
commercial laboratory 
493 HIV-1 WB 491/493 (99.6) 
[2 specimens HIV-2 positive] 
Not reported A CC,DD 
Torian; 201188 Multispot Prospectively collected and 
tested diagnostic specimens 
from New York City testing sites 
8,678 HIV-1 WB 8,644/8,678 (99.6) Not reported  AA,DD,FF 
Ramos; 2013146  Multispot Retrospective testing of 21,317 
diagnostic specimens from 
Seattle 
413 HIV-1 WB 413/413 (100) Not reported  AA, DD 
Ramos; 2013107 Multispot Retrospective analysis of 46,061 
prospectively collected and 
tested diagnostic specimens 
from Seattle 
871 HIV-1 WB 871/871 (100) Not reported C AA, DD 
Cardenas; 
2013147 
Multispot Previously tested HIV-1 WB-
positive specimens 
141 HIV-1 WB 141/141 (100) Not reported A,C DD 
Styer; 201176 Multispot Prospectively collected 
specimens from 38,257 persons 
in New York State testing sites 
1,546 HIV-1 WB 1,545/1,546 (99.94) Not reported  AA,CC,DD,FF 
Product insert166 Multispot Specimens collected from 
a) known HIV-1 positive persons 
and b) 1,441 high-risk U.S. 
persons  
a) 801 
b) 70 
HIV-1 WB 801/801 (100) 
70/70 (100) 
(99.94–100) A,B,C DD 
1.a.3. HIV-1/HIV-2 Ab differentiation assay sensitivity for HIV-2 
Owen; 200849 Multispot Previously tested HIV-2 
specimens from Ivory Coast 
34 HIV-2 NAT 34/34 (100) Not reported A,D,F CC,DD 
Ramos; 2013107 Multispot Retrospective analysis of 46,061 
prospectively collected and 
tested diagnostic specimens 
from Seattle 
4 HIV-2 immunoblot 4/4 (100) HIV-2 positive;  
3 with positive HIV-1 WB 
Not reported D,F AA 
Product insert166 Multispot Previously tested known HIV-2–
positive specimens  
207 HIV-2 WB and HIV-2 
enzyme IA 
207/207 (100) (99.76–100) A,B,C,D  
Abbreviations: Ag/Ab, antigen/antibody; AIDS, acquired immunodeficiency syndrome; IA, immunoassay; IFA, immunofluorescence assay; NAT, nucleic acid test; WB, Western blot.  
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Evidence Table 1.b. Sensitivity of assays for acute HIV-1 infections, by corresponding section in Summary of Evidence 
Publication Test evaluated Specimen characteristics 
Number of 
specimens Reference standard Outcomes Limitations Strengths 
1.b.1. Sensitivity of third and fourth generation immunoassays for acute HIV-1 infection 
Owen; 200849  
Masciotra; 201146  
Advia  
GS Plus O 
Vitros 
Previously tested specimens 
from seroconversion panels 
obtained from blood donors 
183 specimens from 
15 donors 
HIV-1 RNA NAT 3rd generation IAs detected infection 
12–14 days before Western blot 
positive 
A,F CC,DD 
Masciotra; 201146 
Masciotra; 201366 
GS Ag/Ab 
Architect Ag/Ab 
Previously tested specimens 
from seroconversion panels 
obtained from blood donors 
183 specimens from 
15 donors 
HIV-1 RNA NAT 4th generation IAs detected infection 
19–20 days before Western blot 
positive 
A,F CC,DD 
Patel; 201018 Pooled APTIMA Prospectively collected 
specimens from high-risk 
persons in U.S. HIV testing 
sites 
1,162 HIV-1 positive 
specimens  
3rd generation IA 
4th generation IA 
Pooled NAT detected 2.2% more 
infections than 3rd generation IA and 
0.7% more than 4th generation IA 
 AA,CC,DD,FF 
Pandori; 200971 GS Plus O 
Architect Ag/Ab 
Previously tested specimens 
from high-risk persons in San 
Francisco testing sites 
64  HIV-1 RNA NAT 3rd generation IA detected 42.2% 
(27/64) of infections detected by NAT, 
4th generation IA detected 89.1% 
(57/64) 
A,F CC,DD 
Masciotra; 201146 
Nasrullah; 201347 
Western blot 
GS Plus O 
Advia  
Vitros 
Architect Ag/Ab 
GS Ag/Ab 
Previously tested specimens 
from seroconversion panels 
obtained from blood donors 
228 specimens from 
26 seroconverters 
HIV-1 RNA NAT Number of HIV-positive specimens 
detected by 
WB: 56 
3rd generation assays: 108–111 
4th generation assays: 131–135 
A,F CC,DD 
1.b.2. Sensitivity of HIV-1/HIV-2 differentiation assay for acute HIV-1 infection 
Owen; 200849  
Masciotra; 201146 
Multispot Previously tested specimens 
from seroconversion panels 
from blood donors 
183 specimens from 
15 donors 
HIV-1 RNA NAT Multispot became reactive 7 days 
before Western blot positive 
A,F CC,DD 
Nasrullah; 201347 Multispot Previously tested 
seroconversion panels from 
U.S. blood donors 
228 specimens from 
26 seroconverters 
HIV-1 RNA NAT Number of specimens detected by  
WB: 56 
Multispot: 90 
A,F CC,DD 
Styer; 201176 Multispot Prospectively collected 
specimens from 38,257 
persons in New York State 
testing sites 
1,659 3rd generation 
IA repeatedly 
reactive 
Positive HIV-1 NAT 
or follow-up test 
30 positive Multispot results in 
specimens negative or indeterminate 
by HIV-1 WB 
D,F AA,CC 
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Publication Test evaluated Specimen characteristics 
Number of 
specimens Reference standard Outcomes Limitations Strengths 
Ramos; 2013107 Multispot Retrospective analysis of 
46,061 prospectively collected 
and tested diagnostic 
specimens from Seattle 
599 3rd generation, 
and 394 4th 
generation IA 
repeatedly reactive 
Follow-up test  Positive differentiation assay results in 
11 specimens with indeterminate HIV-
1 WB; positive on follow-up test in 6 
patients located 
F AA,DD 
Linley; 2013149 Multispot 3rd generation repeatedly 
reactive, WB negative or 
indeterminate previously tested 
specimens from public health 
laboratories 
570 HIV-1 WB 
negative or 
indeterminate 
specimens  
HIV-1 RNA NAT 27 positive differentiation assay results 
in specimens with positive HIV-1 NAT 
results 
A,E,F DD 
Wesolowski; 2013148 Multispot 3rd generation repeatedly 
reactive, WB negative or 
indeterminate previously tested 
specimens from a commercial 
laboratory 
3,273 HIV-1 WB 
negative or 
indeterminate 
specimens  
HIV-1 RNA NAT 88 positive differentiation assay results 
in specimens with positive NAT results 
A,E,F DD 
Abbreviations: Ag/Ab, antigen/antibody; IA, immunoassay; NAT, nucleic acid test; RNA, ribonucleic acid; WB, Western blot. 
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Evidence Table 2. Specificity of assays, by corresponding section in Summary of Evidence 
Publication Test evaluated Specimen characteristics 
Number of 
specimens Reference standard 
Specificity 
n negative/n tested (%) 
95% confidence 
interval Limitations Strengths 
2.a. Specificity of third generation assays  
Masciotra; 201146 GS Plus O Previously tested specimens from 
blood donors  
414 Negative on 11 IAs or 
negative HIV-1 WB 
and HIV-1 NAT 
412/414 (99.52) 98.26–99.87 A,D CC 
Nasrullah; 201347 GS Plus O Prospectively collected specimens 
submitted for diagnostic testing to a 
commercial laboratory  
10,012 Negative on 3rd and 
4th gen IA or HIV-
1/HIV-2 differentiation 
IA and HIV-1 NAT 
10,010/10,012 (99.98) 99.93–100% D AA,CC,FF 
Owen; 200849 GS Plus O  Previously tested specimens 
collected from blood donors 
513 Negative on 11 IAs or 
negative HIV-1 WB 
and HIV-1 NAT 
510/513 (99.4) Not reported A,D CC 
Wesolowski; 
201194 
a) GS Plus O 
b) VITROS 
c) Advia  
Previously tested specimens from 
blood donors 
a) 1,510 
b) 1,484 
c) 1,486 
Negative 3rd 
generation IA and 
pooled HIV-1 NAT 
a) 1,500/1,510 (99.34) 
b) 1,461/1,484 (98.45) 
c) 1,473/1,486 (99.13) 
a) 98.79–99.68 
b) 97.68–99.02 
c) 98.51–99.53 
a) A,D 
b) A,D 
c) A,D 
a) CC,DD,FF 
b) CC,DD,FF 
c) CC,DD,FF 
Dubravac; 2013168 GS Plus O Prospectively collected and tested 
specimens submitted for diagnostic 
testing to public health laboratory 
2,024 Negative HIV-1 WB 
and HIV-1 NAT 
2,020/2,024 (99.80) 99.49–99.94  AA,CC,DD,FF 
Product insert157 GS Plus O Previously tested specimens from 
blood donors  
11,159 Negative 3rd 
generation IA and 
pooled HIV-1 NAT 
11,147/11,159 (99.89) 99.83–99.96 A,B,C,D DD,FF 
Product insert158 VITROS Specimens from low risk 
populations (pregnant women, 
insurance applicants, children) 
1,438 Negative 3rd 
generation IA or HIV-1 
WB 
1,432/1,438 (99.58) 99.09–99.85 A,B,C,D FF 
Product insert159 Advia  Specimens from low risk 
populations (healthy adults and 
prenatal women) 
6,060 Negative 3rd 
generation IA or HIV-1 
WB  
6,052/6,060 (99.90) 99.78–99.96 A,B,C,D FF 
Mitchell; 2013141 a) VITROS 
b) Advia  
Previously tested specimens from 
blood donors 
a) 994 
b) 1,000 
Negative pooled HIV-1 
NAT 
a) 991/994 (99.7) 
b) 1,000/1,000 (100) 
a) 99.1–99.9 
b) 99.6–100 
a) A 
b) A 
a) CC 
b) CC,DD,FF 
2.b. Specificity of fourth generation assays 
Masciotra; 201146 Architect Ag/Ab Previously tested specimens from 
blood donors 
414 Negative on 11 IAs or 
negative HIV-1 WB 
and HIV-1 NAT 
414/414 (100) 99.08–100.00 A CC,DD 
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Publication Test evaluated Specimen characteristics 
Number of 
specimens Reference standard 
Specificity 
n negative/n tested (%) 
95% confidence 
interval Limitations Strengths 
Nasrullah; 201347 GS Ag/Ab Prospectively collected specimens 
submitted for diagnostic testing to a 
commercial laboratory 
10,012 Negative on 3rd and 
4th gen IAs or HIV-
1/HIV-2 differentiation 
IA and HIV-1 NAT 
10,003/10,012 (99.91) 99.84–99.96 D AA,CC,FF 
Chavez; 201172 Architect Ag/Ab Previously tested specimens from 
blood donors and high-risk 
populations 
7,551 Negative 3rd 
generation IA and 
HIV-1 NAT 
7,513/7,551 (99.5) 99.31–99.64 A DD,FF 
Bentsen; 2011143 GS Ag/Ab Specimens from a) low-risk 
populations (routine testing, 
repositories, commercial vendors) 
and b) high-risk STD clinic 
a) 6,100 
b) 960 
Negative 3rd gen IA or 
HIV-1 WB 
a) 6,089/6,096 (99.89) 
b) 959/93 (99.90) 
a) 99.76–99.94 
b) 99.41–99.98 
A,C,D DD,FF 
Dubravac; 2013168 Architect Ag/Ab Prospectively collected and tested 
specimens submitted for diagnostic 
testing to public health laboratory 
2,024 Negative HIV-1 WB 
and HIV-1 NAT 
2,021/2,024 (99.85) 99.57–99.97  AA,CC,DD,FF 
Product insert160 Architect Ag/Ab Prospectively collected specimens 
from low risk populations 
6,127 Negative 3rd gen IA or 
HIV-1 WB and HIV-1 
NAT 
6,113/6,127 (99.77) 99.62–99.88 B,C,D DD,FF 
Product insert161 GS Ag/Ab Specimens from low risk 
populations (insurance applicants, 
pregnant women, military recruits) 
6996 Negative 3rd gen IA or 
HIV-1 WB and HIV-
1/HIV-2 differentiation 
IA 
6,987/6,996 (99.87) 99.76–99.93 B,C,D DD,FF 
Mitchell; 2013141 a) GS Ag/Ab 
b) Architect 
Ag/Ab 
Previously tested negative 
specimens from blood donors 
a) 1,000 
b) 998 
Negative pooled HIV-1 
NAT 
a) 1,000/1,000 (100) 
b) 995/998 (99.7)  
a) 99.6–00 
b) 99.0–99.8 
a) A  
b) A 
a) CC,DD,FF 
b) CC,DD 
2.c. Specificity of HIV-1/HIV/2 antibody differentiation assay  
Masciotra; 201146 Multispot Previously tested specimens from 
blood donors 
414 Negative on 11 IAs or 
negative HIV-1 WB 
and HIV-1 NAT 
410/414 (99.03) 97.54–99.61 A,D CC,DD 
Delaney; 201163 Multispot Previously collected specimens 
from high-risk populations 
4,799 Negative 3rd gen IA or 
HIV-1 WB 
4,768/,4799 (99.35) 99.08–99.56 A,C,D DD,FF 
Product insert166 Multispot Prospectively collected specimens 
from low- and high-risk populations  
1,495 Negative 3rd 
generation IA or HIV-1 
WB 
1,494/1,495 (99.93) 99.79–100.00 B,C AA,DD,FF 
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Publication Test evaluated Specimen characteristics 
Number of 
specimens Reference standard 
Specificity 
n negative/n tested (%) 
95% confidence 
interval Limitations Strengths 
2.e. Specificity of NAT 
Owen; 200849 Procleix  Previously tested specimens from 
blood donors  
513 Negative 3rd 
generation IA or HIV-1 
WB 
511/513 (99.6) Not reported A,D DD 
Pilcher; 200216 Pooled Roche 
HIV-1 NAT 
Prospectively collected specimens 
submitted for diagnostic testing to 
North Carolina public health 
laboratory  
8,155 IA-
negative;  
5 HIV-1 NAT 
positive 
IA and WB testing of 
follow-up specimens 
from persons with 
reactive HIV-1 NAT 
8,151/8,155 (99.95); 
1 of 5 persons with reactive 
NAT results did not 
seroconvert  
Not reported C AA,FF 
Patel; 201018 Pooled APTIMA  Prospectively collected specimens 
submitted for diagnostic testing to 
Florida public health laboratory 
54,253 IA 
negative;  
15 HIV-1 NAT 
positive 
IA and WB testing of 
follow-up specimens 
from persons with 
reactive NAT 
54,241/54,253 (99.98) 
3 of 15 persons with reactive 
NAT results did not 
seroconvert 
Not reported C AA,DD,FF 
Abbreviations: Ag/Ab, antigen/antibody; IA, immunoassay; NAT, nucleic acid test; WB, Western blot.  
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Evidence Table 3. Accuracy of the previous and recommended diagnostic algorithms, by corresponding section in Summary of Evidence 
Publication Study design 
Specimen 
characteristics 
Number of 
specimens Reference standard Correct results N (%) Limitations Strengths 
3a. Accuracy of algorithms for established HIV-1 infection 
Styer; 201176 Retrospective analysis of 
data from prospective 
testing (GS Plus O 
repeatedly reactive) 
Prospectively collected 
specimens from 38,257 
persons in New York 
State testing sites  
1,578 HIV-
positive 
HIV-1 WB, HIV-1 NAT, 
follow up test results 
Previous: 1,546/1,578 (98)  
Recommended: 1,578/1,578 (100)  
D AA,CC,FF 
Delaney; 201170 Retrospective testing of 
frozen specimens  
Previously tested 
specimens from 3,447 
high-risk persons in HIV 
testing sites 
367 WB- 
positive 
3rd gen IA repeatedly 
reactive, WB positive 
Previous: 367/367 (100) 
Recommended: 367/367 (100) 
A CC,DD 
Wesolowski; 
201194 
Retrospective testing of 
frozen specimens 
Previously tested 
specimens from known 
HIV-positive, high-risk, 
and HIV-negative blood 
donors 
4,828 total 
specimens,  
2,202 WB-
positive 
3rd gen IA repeatedly 
reactive, WB positive 
Previous: 2,202/2,202 (100) 
Recommended: 2,201/2,202 (99.95) 
A CC,DD,FF 
Masciotra; 201146 Retrospective testing of 
frozen samples with 3rd 
generation and 4th 
generation IAs 
Previously tested 
specimens from plasma 
donors 
830 total 
specimens, 
416 WB-positive 
WB positive 3rd gen IA: 
Previous: 416/416 (100) 
Recommended: 415/416 (99.8) 
4th gen IA: 
Previous: 415/416 (99.8) 
Recommended: 415/416 (99.8) 
A CC,DD 
Nasrullah; 201347 Prospective testing and 
retrospective testing, 
frozen specimens, GS Plus 
O and GS Ag/Ab  
Specimens submitted for 
diagnostic testing to a 
commercial laboratory 
n=10,014 
prospective,  
2 WB-positive;  
491 previously 
tested HIV-1;  
2 HIV-2 
3rd gen or 4th gen IA 
repeatedly reactive; HIV-1 
WB, HIV-2 WB 
Previous: 493/495 (99.6) 
Recommended: 495/495 (100) 
A CC 
Bennett; 2013123 Retrospective comparison 
of GS Plus O and Architect 
Ag/Ab  
Previously tested 
diagnostic specimens 
submitted to public 
health laboratory 
29 HIV-1 WB 
positive 
HIV-1 WB Previous: 29/29 (100) 
Recommended: 29/29 (100) 
F AA,CC,DD 
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Publication Study design 
Specimen 
characteristics 
Number of 
specimens Reference standard Correct results N (%) Limitations Strengths 
3b. Accuracy of algorithms in specimens from persons with acute HIV-1 infection 
Masciotra; 201146 Retrospective testing of 
frozen specimens with GS 
Plus O, Advia, Vitros, 
Architect Ag/Ab 
Previously tested 
specimens from 
seroconversion panels 
from blood donors 
228 HIV-1 RNA NAT positive, 
HIV-1 WB negative  
Previous: 0 
Recommended: 
14 acute after initial 3rd gen IA 
36 acute after initial 4th gen IA 
A CC,DD 
Nasrullah; 201347 Retrospective testing of 
frozen specimens with GS 
Plus O, GS Ag/Ab 
Previously tested 
specimens from 
seroconversion panels 
from blood donors 
230 HIV-1 RNA NAT positive, 
HIV-1 WB negative 
Previous: 0 
Recommended:  
12 acute after initial 3rd gen IA  
41 acute after initial 4th gen IA 
A CC,DD 
Wesolowski; 
2013148 
Retrospective testing of 
frozen specimens with 
Multispot, APTIMA 
3rd gen IA repeatedly 
reactive specimens 
submitted for diagnostic 
testing to commercial 
laboratory 
3,273 HIV-1 WB 
negative or 
indeterminate 
HIV-1 RNA NAT positive Previous: 0 
Recommended: 96 acute after initial 3rd gen IA 
A,E CC,DD,FF 
Linley; 2013149 Retrospective testing of 
frozen specimens with 
Multispot, APTIMA 
3rd gen repeatedly 
reactive specimens 
diagnostic specimens 
from public health 
laboratories 
570 HIV-1 WB 
negative or 
indeterminate 
HIV-1 RNA NAT positive Previous: 0 
Recommended: 19 acute after repeatedly reactive 
3rd gen IA 
A,E DD 
Bennett; 2013123 Prospective testing with 
Architect Ag/Ab, Multispot, 
APTIMA 
Specimens from testing 
sites submitted for 
testing to FL public 
health lab  
51,953 total 
specimens 
922 HIV-1 
positive 
Recommended algorithm 
only 
4 (0.4%) of 922 HIV-1 infections identified were 
acute 
NAT required in 74 (0.14%) of all specimens 
submitted 
D AA 
Goodhue; 2013167 Prospective testing with 
GS Ag/Ab, Multispot, 
APTIMA 
Specimens from testing 
sites submitted to MA 
public health lab 
7,984 total 
specimens 
258 HIV-1 
positive  
1 HIV-2 positive 
Recommended algorithm 
only 
8 (3%) of 258 HIV-1 infections identified were 
acute 
NAT required in 16 (0.2%) of all specimens 
submitted 
D AA 
3c. Accuracy of algorithm in specimens from persons with HIV-2 infection 
Torian; 201188 Prospective testing with 
retrospective data analysis 
Specimens submitted to 
NY City public health lab 
for diagnostic testing 
8,760 3rd gen IA 
repeatedly 
reactive 
HIV-2 immunoassay 
HIV-2 WB 
38 HIV-2 positive: 
26 classified as HIV-1 positive and  
12 as indeterminate by HIV-1 WB 
D AA 
Styer; 201176 Prospective testing with 
retrospective data analysis 
Specimens submitted to 
NY State public health 
lab for diagnostic testing 
1,659 3rd gen IA 
repeatedly 
reactive 
HIV-2 immunoassay 
HIV-2 WB 
HIV-2 NAT 
5 HIV-2 positive: 
5 identified by recommended algorithm;  
5 by previous algorithm 
D AA,CC 
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Publication Study design 
Specimen 
characteristics 
Number of 
specimens Reference standard Correct results N (%) Limitations Strengths 
Nasrullah; 201347 Retrospective testing of 
previously tested frozen 
samples 
Diagnostic specimens 
submitted to a 
commercial laboratory 
493 HIV-1 WB 
positive 
HIV-2 immunoassay 
HIV-2 WB 
Previous: 0 (2 misclassified as HIV-1)  
Recommended: 2/493 (0.4%) HIV-2  
D CC 
3d. Accuracy of algorithm in specimens from persons not infected with HIV 
Styer; 201176 Prospective testing with 
retrospective data analysis 
Specimens submitted to 
NY State public health 
lab for diagnostic testing 
33,257 NY State algorithm:  
HIV-1 WB, Multispot, HIV-
1 NAT, HIV-2 NAT, follow-
up specimens 
Recommended algorithm:  
39 fewer indeterminate/inconclusive results, with 
17 fewer in HIV-negative individuals;  
1 false-positive by both previous and 
recommended algorithm 
 AA,CC,DD,FF 
Nasrullah; 201347 Prospective testing of fresh 
specimens; retrospective 
testing of frozen 
specimens  
Specimens from low-risk 
population submitted to a 
commercial laboratory; 
seroconversion panels 
from blood donors 
10,014 
prospective 
specimens; 
230 specimens 
from 
seroconversion 
panels 
HIV-1 WB 
HIV-1 NAT 
Recommended algorithm:  
2 fewer indeterminate results in specimens from 
low risk population; 
39 fewer indeterminate results after 4th gen 
screening of seroconversion panel specimens 
 AA,CC,DD,FF 
Bennett; 2013123 Prospective testing with 
recommended algorithm 
Diagnostic specimens 
from high-risk persons 
submitted to FL public 
health lab 
51,953 HIV-1 NAT for repeatedly 
reactive 4th gen, Multispot 
negative or indeterminate 
One follow-up specimen  
Recommended algorithm:  
69 fewer inconclusive results from negative 
individuals resolved by NAT; 
1 false-positive based on follow-up specimen 
testing 
C AA,DD,FF 
Abbreviations: Ag/Ab, antigen/antibody; IA, immunoassay; NAT, nucleic acid test; RNA, ribonucleic acid; WB, Western blot. 
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